Index

Note:
Abbreviations used in the index are listed on pages xxx–xli.
Alphabetization order: This index is in word-by-word order, whereby terms like ‘duct obstruction’ precede ‘ductal’.
Cross-reference targets in italics refer to general entries, or to subentries within the same main entry.
Page numbers in bold refer to pages on which tables or boxes appear; page numbers in italics refer to figures.
vs denotes differential diagnosis, or comparisons.

a
ABC-02 trial 1092, 1094
ABCC8 gene mutations 31, 32
abdominal compartment syndrome (ACS) 205, 261–262, 313
acute pancreatitis 205, 259, 261–262, 313
chronic pancreatitis pain 350, 422
necrotizing pancreatitis 291
abdominal hypertension 205, 261, 262, 313
abdominal pain acute pancreatitis 219, 222
autoimmune pancreatitis 506, 522, 535, 556
chronic pancreatitis see chronic pancreatitis
pancreatic cancer see pancreatic cancer
abdominal ultrasound
autoimmune pancreatitis 550–551
chronic pancreatitis 406
pancreatic cancer 771
pancreatic neuroendocrine tumors 949, 950
abscesses, pancreatic 241, 302, 305, 316, 318, 441
accessory pancreatic duct (duct of Santorini) 16
anatomy 11, J1
development 4, 5
incomplete fusion with duct of Wirsung 26
small, pancreas divisum and 26
ACE inhibitors, acute pancreatitis due to 233
acetaldehyde 137, 138
acetaldehyde dehydrogenase (ALDH) 137, 140
ALDH2 gene variants 140–141, 345
groups (ALDH1, ALDH2) 140
acetylation, epigenetic, acute pancreatitis 336
acetylcholine (ACh) acinar cell stimulation 43, 44, 44, 45, 51–52, 88
mechanism 48, 48–50, 49
CCK-RP release 85, 88
nicotinic receptors 674, 675
PIP2 breakdown 48, 48
release by pancreatic neurons 85, 88
acetylic acid 423
acinar cell(s) 3, 43, 160
absence/loss 13
in acinar tubules 13
acute pancreatitis initiation 64
see also acute pancreatitis
alcohol metabolism 137
apoptosis 69, 69–70, 109
calbindin B role 69, 69–70, 180
blood supply 22, 252
Ca2+ entry/exit control 50–51, 51, 67
calcium dysregulation, acute pancreatitis 158–159
chronic pancreatitis etiology 334
culture, growth in 101
cytosplasm 15, 16
dedifferentiation 100, 101
differentiation/development 5, 6
malignancies with 683
digestive enzyme release 43, 196, 426
digestive enzyme synthesis control 95, 178
ductal hypertension effect 149
ductal metaplasia, carcinogens 675
fluid secreted see acinar fluid
focal dysplasia, smoking and 676
functions 15, 43, 178
histology 14–16, 16, 17
inflammatory pathways, acute pancreatitis 67–68
injury
alcohol effects 136, 136, 137–138, 336
cigarette smoke effect 676
cytokines/mediators released 71–72, 252, 338
in vitro 63
inflammatory cell infiltration 71, 338
ischemic 252
trypsin role 68, 68–70, 175, 178–179, 242
islet cells, structural relationship 123–124
islet hormones, exposure to 124
membrane capacitance 52
mitochondria 15, 17, 46–47
necrosis 194, 196, 196
pancreatic stone protein (PSP/Reg) expression 127
protection from enzyme activation 64–65, 178–179
response to stress 336
secretion, physiology 43–55, 426
ACh and Ca2+ signal generation 48, 48–50, 49
ACh and CCK stimulating 43, 44, 44, 45, 51–52, 67
Ca2+, abnormal levels, acute pancreatitis 67, 149
Ca2+ control of enzyme secretion 51–52, 57
Ca2+ control of fluid secretion 52, 57
Ca2+ entry/exit 50–51, 51, 67
Ca2+ homeostasis, organelles 46, 46–48, 47
Ca2+ signal generation mechanisms 48, 48–50, 49
Ca2+ signaling 45, 45, 46, 46, 47, 67, 149
Ca2+ transport 46, 46–48, 47
chloride–rich fluid 43, 44, 44–45, 52, 56–57
Cl− exit from cells 52
dangers of Ca2+ signaling 52–53
of digestive enzymes 16, 18, 43, 44, 44–45, 56–57

© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
Companion website: www.wiley.com/go/beger/thepancreas

Companion website: www.wiley.com/go/beger/thepancreas
acinar cell(s) (cont’d)
  inhibition, by caerulein, in models 65, 65
  inhibition reversal effect 66
  pancreatic juice composition 43
  prevention by elevated ductal pressure 149
  repetitive Ca2+ spiking 50, 52, 53
  sequential, with duct cells 56–57
  store-operated Ca2+ channels 45, 50–51, 51
  see also digestive enzymes
  staining 14, 17
  stimulation, pancreatitis models 63
  tight junctions between 15, 52
  transition to ductular-like cells 14, 98
  ultrastructure 14, 15–16, 16, 17
  volume of pancreas 43
  ultrastructure 13–16

  tele-insular 123
  peri-insular (around islets) 123, 124
  early degeneration 30
  blood supply 252
  arrangements 13–14, 123
  “acinar–duct–islet axis” 123, 124
  see also insulo-acinar relationship
  acinus (acini) 43
  arrangements 13–14, 123
  blood supply 252
  early degeneration 30
  low blood flow, damage 252
  peri-insular (around islets) 123, 124
  tele-insular 123
  ultrastructure 13–16
  acquired immune deficiency syndrome (AIDS) 232
  ACTH, PanNETs secreting 955, 956
  medical treatment 973
  activated protein C (APC) 184
  acute biliary pancreatitis (ABP) 146–157
  cholecystectomy after, timing 153, 299, 328, 357
  clinical features 152
  diagnosis 296
  endoscopic therapy 296–300
  adverse events 297
  cholecystectomy after 299
  early treatment, benefits 298
  indications for 296–297
  outcomes and timing 297–299, 328
  stone extraction 297, 298
  techniques 297
  epidemiology 146, 150–151, 296
  etiology 146–150, 296
  bile reflux 146, 147
  common channel hypothesis 146–147, 149
  ductal hypertension hypothesis 148–149
  duodenal reflux hypothesis 147–148
  gallstone mechanisms 146–149, 296
  microlithiasis 151, 151
  other causes (non-gallstone) 149, 149–150
  two-phase hypothesis 149
  gallstones 146–149, 160, 193, 196, 260, 296, 355
  confirmation of presence 151–152
  management 260
  obstruction and resolution 149
  size and number 151
  histopathology 196
  natural course 196
  mortality rate 152
  imaging 238–241
  validation and comparison 200, 201, 241
  see also acute pancreatitis, severity assessment
  clinical features 219, 222, 258
  see also pain, acute pancreatitis
  clinical pathway for managing 258–260, 259
  coagulopathies 184–185
  congenital anomalies and see congenital anomalies
  costs of 63, 251
  creatinine (serum) 207, 209, 262
  cytokines 71, 162, 208, 209
  definition 193, 219
  diabetic ketoacidosis 231, 262
  diagnosis 238, 239
  discharge planning 357
  drug-related 232–234, 234
  early intra-acinar events 64–72, 324
  autophagy pathways 70
  calcium signaling 67
  cathepsin B role in apoptosis 69, 69–70, 180
  colocalization, zymogens/lysosomes 66, 66
  ER stress 70–71
  inflammatory pathway activation 64, 67–68, 71
  inhibition of secretion 65, 65–66
  innate immune system activation 67
  mitochondrial dysfunction 70
  systemic injury after 71–72, 252
  trypsin role, acinar cell injury see below
  early management 258–260, 259
  ECG abnormalities 185–187
  ectopic pancreatic tissue 215
  emetogenic see acute pancreatitis, interstitial edematous
etiology 230, 296, 355, 417
alcohol see alcohol-induced acute pancreatitis
bile reflux 146, 147
biliary surgery causing 150
congenital anomalies see congenital anomalies
cystic lesions 327
drugs causing 232–234, 234
gallstones see acute biliary pancreatitis
hypertriglyceridemia mechanism 262
infectious diseases 231–232, 232
examination for 258
fatty acid ethyl esters (FAEE) 186
fluid collections after 311–312
conservative treatment 312–314
endoscopic management 301–304
minimally invasive therapy 313–314
surgical management 305–310
see also pancreatic fluid collections (PFC)
follow-up 327–328
free fatty acids, increased 186
fungal infections 252, 266
genetic factors 158–165, 159
multiple genetic defects 161
see also genetic susceptibility factors
gut permeability 183–184, 184
-gut–lymph composition changes 168
gut–lymph toxicity 169, 169
hematocrit 207, 209, 259
in hereditary pancreatitis 375–376
histopathology 193–198, 335
etiology related to 196–197
pathophyslogic mechanisms 196–197
type 1 necrosis pattern 193, 194, 196, 197
type 2 necrosis pattern 194, 196, 196, 197
type 3 necrosis pattern 194, 196, 196, 197
unsolved questions 197
see also necrosis, in acute pancreatitis
historical aspects 178
hypercalcemia and 230
hypertriglyceridemia 230–231, 234, 262
hypocalcemia 186–187
hypomagnesemia 186–187
hyperperfusion 258, 260
hypotension 261
hypovolemia 258, 260
hypoxemia 181
“idiopathic” 150, 151, 213
children 222
imaging 238–250
classification/severity grading 238–241, 239, 240
CT Severity Index 244–245
diagnostic criteria 239
limitations/pitfalls 245–248
of local complications 240, 242–244
long-term complications 327
severe pancreatitis 241, 241–242
staging of severe pancreatitis 244–245, 248
incidence 63, 251, 311, 355, 417, 418
infectious complications 265–266, 267
prevention 266–267
inflammatory response, and cytokines 71, 162, 208, 209
interleukins (IL-6, IL-8) 208, 209
interstitial edematous 193, 194, 305, 311
histopathology, initial phase 193, 194, 195, 241
management 313
outcome 194–195
radiographic diagnosis 241, 241–242
laboratory variables 207–208, 209, 258, 260
local complications 265, 266, 306, 316
acute necrotic collection 195, 242–243, 243, 266
APFC 242, 243, 266
diagnosis/imaging 240, 242–244
fistula formation 316
infections 265, 267
need for early diagnosis 248
pseudocysts 244, 245, 266, 316
revised Atlanta classification 242, 306
“walled-off” necrosis 195, 239, 242, 243, 244, 241, 265, 266
long-term complications 323, 325, 327
cancer and death 327
chronic pancreatitis 324, 325
diabetes mellitus 326
endocrine pancreas dysfunction 323, 324, 325, 328
exocrine pancreas dysfunction 323, 324–325, 325, 328
imaging findings 327
incisional hernia 327
pain 323, 326, 326–327
risk factors 324, 326
long-term outcome 323–330, 325, 326
quality of life 326–327, 357, 359
see also long-term complications (above)
magnesium deficiency 186
metabolic/systemic disorders and 230
modified DBC classification 202
models see experimental pancreatitis
moderately severe 199–200, 200, 205, 241
molecular/biochemical
abnormalities 178–181
cathepsin B 69, 69–70, 180–181
digestive protease activation 64–68, 178–180, 196–197
monitoring 312
mortality 178, 181, 271, 312, 327, 355
natural course 178, 260, 261
necrosis in see necrosis, in acute pancreatitis
necrosis–fibrosis sequence 323
necrotizing see necrotizing pancreatitis
neurogenic inflammation see neurogenic inflammation
neutrophil-inducing local injury 71–72
organ failure 178, 181, 184, 205
dynamics 205
early, and persistent 205
modified DBC classification 202, 202
multiorgan 178, 181
see also multiple organ dysfunction syndrome (MODS)
pancreas divisum 213, 214
in pancreatic cancer 327, 718
pancreatic cystic neoplasms and 569
pancreatic microcirculation 251–252
pancreatic stem cells 20, 109
paralytic ileus 183–184, 184, 262
parathyroid hormone, increased 186
pathogenesis 178–179, 196–197
in periampullary tumors 1038
phases 64
as polyfactorial disease 135, 138, 159
primary hyperthyroidism and 230
procalsitonin (PCT) 208, 209
prognostic factors 244–245
quality of life 326–327, 357, 359
readmissions for 355–357, 356
risk factors 356, 357
recurrent (RAP) 325, 325, 355, 417
burden/incidence 357, 417, 418
in children 226–227
chronic pancreatitis risk after 195, 359
chronic pancreatitis risk after 195, 359
in cystic fibrosis 393, 398
first recurrence 357
hereditary pancreatitis 374, 376, 746
histomorphologic pathways 323
inborn errors of metabolism 33
natural history 355–359
prevention 302
risk and risk factors 324, 357, 358, 359
risk/risk factors 357, 359
second/further recurrences 359
renal failure 183, 262
response to, MDP 1–2518A/G mutation 162
risk factors 159, 159
for recurrence 324, 357, 358, 359
serum amyloid A (SAA) 208
severe 200, 205, 239, 241
contrast CT avoidance 260
definition 204
edematous see acute pancreatitis, interstitial edematous
Index

acute pancreatitis (cont’d)
treatment (ICU) 258–264
intestine role 167–168, 168
necrotizing see necrotizing pancreatitis
radiologic diagnosis 241, 241–242, 245–248
radiologic staging 244–245
severity 197, 265, 311, 355
classifying, reasons for 199, 201, 202
cytokine polymorphisms 162
semantic modifying factors 161–162
reduced, reversal of secretion
inhibition 66
severity assessment 204–212, 209
Balhazar’s CT system 238
CT Severity Index 244–245
CT Severity Index, modified 248
CT system/grades 238–239, 244–245
historical perspectives 204
imaging 204
Japanese CT Severity Index 245
laboratory variables 207–208, 209
objective criteria 204
see also acute pancreatitis, classification systems
severity scoring 205–207, 209
APACHE II score 206, 209
in children 224
Imrie/Ranson 205, 209
Marshall 205, 209
organ failure-related 206–207
SOFA 206, 207–209, 209
systemic abnormalities in 181–185, 252
systemic injury, inflammatory 71–72, 252
treatment (antibiotics) 265–270, 313
choice of drug 268–269, 313
clinical studies 267, 268
on demand 268
indications 267–268, 313
limitations 269
necrosis with infection 267–269, 272
prophylactic 266–267, 313
rationale for 266–267
treatment (conservative) 251–257, 312–314
basic support 312
enteral/parenteral nutrition
254–255, 313
fluids see fluid resuscitation
treatment (ICU) 258–264
admission, indications 260–261
early management 261–262
initial and second phases 261
late management 262–263
of metabolic abnormalities 262
pre-ICU management 258–260
special considerations 260
transition planning 263
treatment (surgical) see under necrotizing pancreatitis
trypsin role 68–71
acinar cell injury mechanism 69, 69–70, 178–179, 242
second phase of activation 71–72
tryptophan metabolites 168
walled-off necrosis after 195, 239, 242, 243, 244, 245, 266
walled-off necrosis treatment strategies 301–304
endoscopic 301–304
surgical 305–310
acute peripancreatic fluid collection (APFC) 195, 242, 243, 266, 311, 313
definition 242, 311
see also pancreatic fluid collections (PFC)
acute-phase proteins
acute pancreatitis severity 207–208
SPINK1 protein 160
acute recurrent pancreatitis (ARP) see acute pancreatitis, recurrent
case fatality rate 204
early management 261–262
late management 262–263
initial and second phases 261
admission, indications 260–261
see fluids
prophylactic 266–267, 313
necrosis with infection 267–269, 272
limitations 269
SOFA 206, 207–208, 209
clinical studies 267, 268
choice of drug 268–269, 313
ADH1B gene 140
age
afferent loop syndrome 910
AE2 and AE4 56, 59
ADH1B gene 140
ADH III 137
ADH I (ADH1C) 137, 140
acute respiratory distress syndrome (ARDS) 181–183, 261
adenoma
ampullary see ampullary adenoma
insulin-producing 31
solid serous 699
villous, periampullary 1040, 1047, 1058–1059, 1068, 1074
ADHIB gene 140
adrenergic innervation, pancreas 88
adenomediun 123, 127
adverse drug reactions, classification 233
AE2 and AE4 56, 57, 59
afferent loop syndrome 910, 910
age
IPMN 570, 612–613, 707
pancreatic cancer 776
pancreatic cysts 568, 568
agense of pancreas 24
partial 24–25
AIP see autoimmune pancreatitis (AIP)
air embolism 281
alanine transaminase (ALT) 152, 152
albumin 186, 262
alcohol
antimicrobial see antimicrobial drugs
effect on pancreas 136, 136
duct cells 136, 136
pancreatic stellate cells 136, 136
effects on pancreas 343–344, 344, 345
epigenetic proteins affected by 355
metabolism by pancreas 137, 343
metabolites, effects on pancreas 343–344, 344
as modifier in chronic pancreatitis 336
withdrawal syndrome 263
alcohol consumption
abuse/heavy drinking/misuse 342, 343
acute pancreatitis 135, 138
chronic pancreatitis 336, 342, 343
diabetes in chronic pancreatitis 469
pancreatic cancer risk 476
survival rates 397
alcohol-induced acute pancreatitis
acute see alcohol-induced acute pancreatitis
acute and chronic, as continuum 135
chronic see alcoholic chronic pancreatitis
as clinical paradox 135
cessation/abstinence 357
chronic pancreatitis pain 423
after pancreatic resection 469
recurrent acute pancreatitis 324
continued, chronic pancreatitis 357, 397
cessation/abstinence 357
dose–response relationship 342–343, 343
alcohol dehydrogenase (ADH) 137, 140, 343
ADH I (ADH1C) 137, 140
ADH III 137
ADHIB gene, variants 140, 345
alcohol-induced acute pancreatitis
alcohol volume causing 135
epidemiology 135–145, 355
etiology and pathogenesis 135–145, 335
alcohol metabolites, toxicity 137, 138
direct cellular effects of alcohol 136, 136–138
historical aspects 135–136
large duct theories 135–136
small duct (protein plug) theory 136
histopathology 196
hypertriglyceridemia in 231
individual susceptibility 138–142, 139
environmental factors 138–140, 139
hereditary factors 138, 139, 140–142
model not available 64, 136–137
as polyfactorial disease 135, 138, 159
recurrence/progression 324
alcohol-metabolizing enzymes 137
polymorphisms 140–141, 345
alcoholic chronic pancreatitis 342–348, 359, 398
abdominal pain, patterns 361, 399
age at diagnosis 417
alcohol consumption levels 342–343, 343, 345, 397
clinical features 361, 399
c-o-predisposing factors 345–346
diabetes in 402
endocrine insufficiency 399
epidemiology 342–343
experimental models 120, 344, 345
genetic susceptibility factors 345–346, 360
macrophage role 119, 120
pain management 423
pancreatic cancer risk 417, 418
pathophysiology 343–345, 398
cofactors involved 345
ethanol metabolism 343
ethanol/metalte effects 343–344, 344
as modifier in chronic pancreatitis 336
withdrawal syndrome 263
alcohol consumption
abuse/heavy drinking/misuse 342, 343
acute pancreatitis 135, 138
diabetes in chronic pancreatitis 467
pancreatic cancer risk 476
survival rates 397
alcoholic chronic pancreatitis 336, 342, 343
acute see alcohol-induced acute pancreatitis
acute and chronic, as continuum 135
chronic see alcoholic chronic pancreatitis
as clinical paradox 135
antibiotics
- in acute pancreatitis see acute pancreatitis, treatment (antibiotics)
- overdose 269
prophylactic
- acute pancreatitis 266–267, 313
- pancreatic fistulas and 318–319
- pancreatic pseudocysts 441–442
- resistance, multidrug, acute pancreatitis 266
- treatment “on demand” 268
- antidiabetic drugs, oral 400, 498–499
- antiepileptic drugs 234
- antinuclear antibodies, autoimmune pancreatitis 510, 540
antioxidant(s)
- adverse effects 437
- deficiency
- chronic pancreatitis 435
- tropical chronic pancreatitis 386
- therapeutic 435, 436–437
- antiprotease treatment 170, 251
- antithrombin III, acute pancreatitis 185
- aorta, pancreas relationship 10, 12, 13
- AP‐1 (activator protein‐1) 138, 344
- atriope 86
- ATRX gene, mutation 938, 939, 940, 941, 942, 943
- ATRX protein 938, 940, 943
- antioxidants
- evidence for use in diagnosis 544–545
- non‐organ/organ‐specific 540
- type 1 autoimmune pancreatitis 510–511, 525, 540, 541–542
- autodigestion of pancreas 64, 316, 344
- see also digestive enzymes
- autoimmune diseases, chronic pancreatitis with 350
- autoimmune pancreatitis (AIP) 350, 503–504, 1037
- diabetes mellitus in 496
- diagnostic criteria (ICDC) 505, 521, 522, 523, 536, 550
- differential diagnosis 517
- pancreatic cancer vs 419, 546, 550, 552
- use of markers 545–546
- endocrine insufficiency after 557, 562
- epidemiology 505–509, 546
- first international survey 505–506
- Japan, nationwide survey 505
- second international survey 506, 507
- third international survey 506–507, 508
- exocrine insufficiency after 557, 562, 562
- Type 1 autoimmune pancreatitis 505, 521, 522, 523, 536, 550
- histology 505, 516–519, 518, 520, 546, 550
- histopathology 368, 550
- historical aspects 520, 521, 534, 539
- imaging diagnosis 550–554
- abdominal CT 411, 523, 525, 551, 551
- abdominal MRI 411–412, 551
- abdominal ultrasound 550–551
- ERCP 523–524, 552
- FDG-PET 524, 526, 528, 529, 551–552, 756
- MRCP 524, 553, 553
- nuclear medicine 551–552
- pancreatic duct imaging 552, 552–553, 553
- parenchyma imaging 550–552, 551
- inflammatory pancreatic head mass vs 366–367
- laboratory diagnosis 539–543
- autoimmunity markers 540, 541–542, 544
- β‐γ globulin bridging 544, 545
- evidence for use of markers 544–549
- IgA and IgM 545
- IgG levels 524–525, 540, 541, 544, 545, 546
- markers, for diagnosis, evidence 544–545
- markers, for differential diagnosis 545–546
- markers, for relapse prediction 546, 546–547
- other markers 541
- serum markers 539–540
- long‐term outcome after therapy 560–564
- exocrine/endorocrine insufficiency 557, 562
- extrapancreatic cancer in 563
- “ordinary” chronic pancreatitis 562
- pancreatic cancer risk 517, 553, 557, 563
- relapse see below
- medical management 555–559, 560
- algorithm 558
- follow‐up 557
- high‐dose steroids 556, 557
- immunomodulators 556, 557, 558
- of initial presentation 556
- low‐dose steroids 556
- of relapse 556–557, 560–561
- rituximab 556, 557, 559, 560
- side‐effects and managing 557–558
- steroids 529, 555, 556–557
- steroids, in type 2 536, 546, 547, 558
- natural history 562, 562
- not otherwise specified (NOS) 521, 523
- pathogenesis 510–515
- autoantibodies 510–511, 525, 544
- B cells and plasmablasts 512
- cytokines/chemokines 511, 511–512
- genetic predisposition 510
- immunologic interactions 512
- plasma cells 512–513
- T cells 511, 511–512
- recrudescence 555–556
- relapse 556, 560–561, 562
- markers to predict 546, 546–547
- medical management 556–557, 560–561
- rates/frequency 560, 562
- symptoms 556
- type 2 507, 508, 536–537, 546, 547
- remission 555
- induction/maintenance 556
- symptoms 505, 506, 521–522
- type 1 505, 520, 521, 534, 539, 550, 555
- autoantibodies 510–511, 525, 540, 540
- blood tests 524–525
- “capsule‐like rim” 522, 551, 551
- clinical features 520–533, 524
- definitive and probable 523
- diagnostic criteria (ICDC) 521, 522
- differential diagnosis 517
- diffuse enlarged pancreas 522–523
- epidemiology 506, 507, 507
- extrapancreatic lesions 526–529, 528, 529
- histology 516–517, 518, 520, 527, 546, 550
- IgG4 see immunoglobulin G (IgG), IgG4
- imaging 522–524, 525, 526
- pathogenesis 510–513, 512, 541, 541
pathology 520, 525–526, 550
patient profiles 521–522
proteomic study 513, 541
steroids, response/relapse 529
storiiform fibrosis 516, 517, 525
symptoms 521–522
treatment, and relapse 507, 508
unclassified 518, 523

B cells (B lymphocytes) 856, 857
CD20 556, 561
type I autoimmune pancreatitis 512, 517, 556

B lymphocytes see B cells (B lymphocytes)
bacteremia, gallstone association 152
bacterial endotoxin see endotoxin, bacterial
bacterial infections
acute pancreatitis 265, 266
complication of 265, 266, 267
etiology of 231, 232
prevention/treatment 266–267
pancreatic abscess 241, 302, 305, 316, 318, 441
spectrum 266
superinfection of pancreatic necrosis 178, 266, 267
bacterial overgrowth 183, 430
bacterial translocation 166, 183, 184, 254
bacterial translocation hypothesis 166
bactibilia 913
BALLARD trial 1092
balloon enteroscopy-assisted ERCP 836
Balthazar system 238
basic helix loop helix (bHLH) transcription factor 6
basilar cell membrane 15
Bax (Bcl-2 apoptosis-promoting protein) 70
Bcl-2 70
BCL-10 701
Beckwith–Wiedemann syndrome (BWS) 31, 33, 701
Beger procedure 367, 368, 450, 453, 491
laparoscopic 485
outcome, Frey procedure vs 491–492
benzo[a]pyrene 674
benzodiazepines 263
Bernard, Claude 146
Berne/Farkas modification, of Beger procedure 367
Berne procedure 450, 485, 491
β-γ globulin bridging 544, 545
β cells 21, 123, 124
ATP-dependent potassium channel (K_{ATP})
defects 31
deficit (number), in chronic pancreatitis, diabetes 495, 496
development 5, 6, 7
dysfunction
in chronic pancreatitis, diabetes and 495, 496
pancreatic stellate cell role 110, 112
immunostaining 21, 21, 22
insulinoma 1002
see also insulin bevacizumab 976
PanNETs 975, 976
treatment 837–838
ampullary tumors 837–838
biliary stent placement 837–838
ampullary tumors 1071
biliary obstruction 149
biliary tract
acute pancreatitis link 146, 147
carcinoma 1051, 1052
extrahepatic, tumors 1083
see also distal cholangiocarcinoma intraepithelial neoplasms 1051–1052
bilirubin, elevated 1038
biochemical makers
acute pancreatitis 207–208
autoimmune pancreatitis 541
pancreatic cancer see pancreatic cancer, tumor markers
PanNETs 956–957
biopsy
ampullary tumors, malignant 1060, 1069
EUS-FNB, ampullary carcinoma 1060
pancreatic cancer 776, 869
pancreatic transplant rejection 1127
bleeding
post-DPPHR 460, 462
post-endoscopic papillotomy 1071
post-laparoscopic surgery 650
narrowing/stenosis 553
type I autoimmune pancreatitis 526, 527, 528, 534
biliary drainage 835
endoscopic stenting 829
ERCP in pancreatic cancer 829, 835
pancreatic cancer 770, 828, 829, 832, 835
surgical treatment 451–452
stones
acute biliary pancreatitis 296
removal 297
strictures
anastomotic, after pancreaticoduodenectomy 911
transmural drainage, infected pancreatic necrosis 280
blood flow, low, in pancreatic acinus 252
blood glucose
perioperative management, insulinoma 1020–1021
after total pancreatectomy 799
type 1 diabetes 1121
type 3c diabetes 497, 497
see also glycemic control; HbA1c; hyperglycemia; hypoglycemia
blood group, non-O, pancreatic cancer risk 746
blood pressure
acute pancreatitis 185, 258
systolic, severe acute pancreatitis 259–260, 261
blood supply
islets of Langerhans 22, 124, 124
pancreas 13, 14, 124, 124, 251–252
blood tests, type 1 autoimmune pancreatitis 524–525
blood urea nitrogen (BUN), acute pancreatitis 207, 209, 262, 312
body mass index (BMI)
chronic pancreatitis 429
pancreatic cancer risk 667, 668, 720
see also obesity
body of pancreas
anatomy 3, 790–791
cancer see under pancreatic cancer
CT image 12
BOLERO-1/BOLERO-3 trials 943
bombedin, pancreatic secretion stimulation 87
bone health, chronic pancreatitis 430
bowel ischemia, post-necrosectomy 286
bowel resection 260
bowel rest 254
bradykinins 233
BRAF gene, mutations, ductal adenocarcinoma 679, 680, 683, 867
branched-chain ketoaciduria 34, 35
BRCA1 gene, mutation 688
pancreatic cancer 689, 746
BRCA2 gene, mutation 679, 683, 746, 869
familial pancreatic cancer 689, 746, 747
breast cancer, familial pancreatic cancer 688, 689
brittle diabetes 431, 497, 798
see also diabetes mellitus, type 3c
Brunner glands, nonampullary duodenal cancer 1052
Büchloer–Bern procedure 492
buprenorphine 423
“burn-out theory”; pain 350, 361
C
C-peptide, insulinoma 954
C-reactive protein (CRP), acute pancreatitis 207–208, 209
CA-125, pancreatic cancer 771
CA12 gene, mutations 59, 60
CA19-9 367, 451, 762
elevated, conditions with 762
cholangiocarcinoma 1038
periampullary tumors 1038
false-positives/-negatives 762, 770
measurement 762, 763
pancreatic cancer 762, 763, 770–771, 776, 906
local recurrence marker 903
normal after neoadjuvant therapy 844
prognosis and 762, 770–771, 910
screening 749
cachexia 368
cADPR (cyclic ADP-ribose) 47, 47–48
caerulein 63
acinic cell culture, growth 101
calcium overloads, acinar cells 52–53
conditionality of secretion by, in models 65, 65
carcinogens 672, 677
castration-resistant CRAC (Ca2+ release activated) 51, 53
store-operated 45
Ca2+-selective CRAC (Ca2+ release activated) 51, 53
store-operated 45
Ca2+ entry 45, 50–51, 51
transport, exocrine pancreas 46, 46–47, 47
tunnel experiments 46
uptake inhibited, zymogen activation prevented 230
calcium-sensing receptor gene (CASR), gene mutations 161, 377
calculi, tropical chronic pancreatitis 385
cancer vaccines 858–860
cancerization
ductal 694, 695, 706
periampullary 1047
Candida, acute pancreatitis association 232, 266
capacitave advanced pancreatic cancer 874, 876
ampullary carcinoma 1093
pancreatic cancer adjuvant therapy 849, 850
capillaries, exocrine pancreas 124, 252
CAPOX therapy 1093, 1094
CAPS3 study 747–748
carbohydrate antigen 19–9 see CA19-9
carbohydrates (dietary)
digestion/metabolism 426
regulation of pancreatic protein synthesis 96
carbon dioxide, exhalation, exocrine function test and 402
fibrogenic anhydrase 59, 59
CA12 59, 60
type II, autoantibodies against 525, 540
carboxyl ester lipase (CEL) 32, 137, 231, 427
hybrid allele (CEL-HYB) 141
carboxypeptidase A1 (CPA1) 179, 427
carcinoembryonic antigen (CEA) 595, 598
mucin-producing cysts 440, 607
neoplastic cysts 603, 604, 607
pancreatic cancer 771
pancreatic cysts 440, 593, 595, 596, 598
serous cystadenoma 603
carcinogen(s) 673
accumulation in pancreatic juice 676
cigarette smoke 673–674, 675, 676, 676
metabolism, enzymes 673–674, 676
carcinogenesis, pancreatic cancer 673–675, 675
carcinoid syndrome, classical 955, 956
medical treatment 973, 974
carcinoid tumors 1019
gallbladder transplant 1025
liver 1024
cardiac output, gut–lymph toxicity and 169, 169
cardiovascular abnormalities
acute pancreatitis 185, 185–186, 261
pancreas transplant and 1123
Carney complex 707
β-carotene 436, 437
caspase-3 70
permutative 70
CA53 gene, mutations 161, 377
cassava 385–386
cholecystokinin-8 (CCK-8) 86, 344
cholecystokinin-releasing factor (CCK-RF) 29
cholecystokinin-releasing peptide (CCK-RP) 85, 85
choledochal cyst 27, 214, 214
acute pancreatitis with 214, 214–215
frequency, clinical features 214
“choledochal window” 75
choledochoele, acute pancreatitis with 214, 214–215
cholesterol polyps 150
cholesterolasia 149, 150
cholinergic pathways 86, 88
chomatin remodeling 940
cholesterolosis 149, 150, 150
chronic pancreatitis 333–502, 406
chromosome deletions, pancreatic
chromosome 3p, loss of heterozygosity 581
chromosome 6, isodisomy 31
chromosomal instability 337–338
chromogranin A 126, 701, 934–935
chromogranin B 953
cholecystokinin-releasing factor (CCK-RF) 29
cholecystokinin-8 (CCK-8) 85, 85
complications 406, 412–413, 439, 458
diagnosis, time interval for 397–398
diabetes mellitus, in chronic
in cystic fibrosis 393
definition/concept 333, 334, 349, 371, 374
diabetes in see diabetes mellitus, in chronic
diagnosis, time interval for 397–398
diagnostic imaging 406, 407–410
abdominal ultrasound 406
CT 406, 407, 407, 408, 454
endoscopic ultrasound 406
MRI and MRCP 406, 407, 407–409, 408, 409, 410
diagnostic path 372
differential diagnosis
autoimmune pancreatitis 411–412, 412
pancreatic cancer 367, 411, 451, 756
pancreatic mass 411, 412
ductal stones in 442
endoscopic therapy 442–444, 443
early 371–373, 406
diagnosis 371, 372, 397–398, 406
imaging 371, 372, 406
endocrine insufficiency 361, 399–400, 495, 496–497
nutritional support 431, 497
see also diabetes mellitus, in chronic
pancreatitis
environmental exposures and 336
epidemiology 342–343, 355, 359, 361, 397, 417, 418
epigenetics 336, 337
etiology 334, 335, 335, 381
focal see groove (duodenal) pancreatitis
fibrosis/fibrotic response 333, 334, 335, 377, 378
fibrogenesis/fibrogenic response 334, 335
fibrosis/fibrotic response 333, 334, 335, 377, 378
macrophage role 119–120, 338
pancreatic stellate cells role 109–110, 117, 338
settings with 337
alcoholic see alcoholic chronic pancreatitis
animal models see experimental
neuropathic 421, 435
abdominal 361, 398–399, 421
pseudocysts causing 350, 440
pseudocyst treatment 440–442
surgical 423–424
outcome 489–490
postoperative 469
neurogenic pain 349, 354, 421–422, 435, 453, 458
“burn-out theory” 350, 361
central involvement 352
compartment syndrome theory 350, 422
ductal hypertension hypothesis 350, 422, 442, 453
GAP-43 and 351
neural/perineural changes 350–351, 421
noninvasive function tests 401–402, 402
provocative tests 400, 401
serum tests 400, 401
neurogenic remodeling 350–352, 421, 453
"neuroimmune interaction" hypothesis 351
NGF and TrkA role 351
oxidative stress 435–436
plumbing theory 421–422
substance P and IL-8 release 352
substance P and NK-1R role 351
in pancreas divisum, gene mutations 26
pancreatic cancer 720–721

differential diagnosis 367, 411, 451, 756
etiologic similarities 417
incidence 417, 418, 721
reverse causality 418
risk 361–362, 417, 418, 451
risk factors 417–420, 669, 720–721, 746
strength of association 417–418, 669, 720–721, 746
risk 361–362, 417, 418, 451
incidence 417,
pathogenesis 333–341, 371
repeated injury and fibrosis 333, 334, 335, 339
sentinel acute pancreatic event model 334–336, 335, 338–339
pathology 109, 333, 334, 374
pseudocysts in 440
outcome of treatment 488–489
treatment 440–442, 488
see also pseudocysts, pancreatic quality of life and survival 362
risk factors 333–334, 349, 359
CFTR gene mutations 337, 391–392, 392
recurrent acute pancreatitis 359
severity, imaging 407
"small duct disease" 455
socioeconomic significance 397
subclinical 323, 336
treatment (conservative) 421–438
antioxidants 435–438
enzyme see enzyme replacement therapy, pancreatic medical 426–428, 435–438, 489
nutritional see chronic pancreatitis, nutritional support
outcome 489–490
pain management see above
treatment (endoscopic) 449, 453
common bile duct obstruction 444
drainage 423, 483–484
ductal stones/stenoses 442–444, 443, 453, 491
indications 439–440
lost stents, failure 453, 454
outcomes 488, 490, 491
pseudocysts 440–442, 441, 488
surgery (open) vs 458, 490
treatment (surgical) 439–502
benefits 459
for biliary obstruction 451–452
choice of procedures 449, 450, 453
comparison of procedures 491–492
DPPHR see duodenum-preserving pancreatic head resection
drainage vs resection, outcome 491–492
endoscopic therapy vs 458, 490
Frey procedure see Frey procedure
goals 449, 459
hemipancreatectomy 459
indications 439–440, 449, 453–454, 458, 469
laparoscopic see laparoscopic surgery
major resection see pancreatic resections
outcomes 488–489, 490, 491–492
pancreatectomy see pancreatectomy
pancreatic duct drainage see pancreatic duct(s)
pancreatoduodenectomy see pancreaticoduodenectomy
resections see pancreatic resections
strategies 439–448
timing 490
tropical see tropical chronic pancreatitis (TCP)
undernutrition 429
vitamin deficiencies 429–430
weight loss 399
chyliomicroenemia 35
chymotrypsin 179, 427
CCK release inhibition 90
gene mutations 141–142
secretion, fecal test and 401
chymotrypsin C (CTRC) 162, 179, 427
CTRC gene mutations 141–142, 162, 427
hereditary pancreatitis 377, 379
primary chronic pancreatitis 387
chymotrypsinogen 162, 427
cigarette smoke carcinogens 673–674
see also smoking
cioliophathy 33
cineradiography, sphincter of Oddi
motility 78
circulating tumor cells (CTC), pancreatic cancer 763, 869
cisplatin 976, 977, 1006, 1011, 1053
distal cholangiocarcinoma 1090
CIT-07 trial 1112, 1115
CK7 and CK20 1048, 1050, 1059, 1075
CT/HCO3-exchangers 56, 57
CLARINET trial 964, 974
claudin 2 141, 162
gene mutations 141, 162, 346
CLDN2 gene mutations 141
Clinical Islet Transplantation (CIT) Consortium 1109, 1112
Clonorchis sinensis 232
closed lavage, lesser sac 290, 291, 291, 317
closed packing 292–293, 293, 293, 317
coupling/laparoscopic 637
acute pancreatitis 184–185
"coffee bean appearance" 607
coffee consumption 186
collapse, deficiency 28–29, 29
Collaborative Islet Transplant Registry (CITR) 1109, 1113
collagen 109
collateral circulation 13
colloid (mucinous) carcinoma 576, 695
invasive IPMN 662, 709
colloid solutions, acute pancreatitis models 253
colocalization, zymogens and lysosomes 66, 66, 69
colonic fistula 317, 320
colonic necrosis 286
colony-stimulating factor 1 (CSF-1), antibodies to 861
common bile duct (CBD)
anatomy 11, 11, 75, 76, 1047
common channel 27, 75, 76
anomalous pancreaticobiliary ductal union 214, 214
common channel syndrome 27, 146–147, 197
conservation, in DPPHR 623, 624, 624
development 4, 5, 724, 725
diameter 76
dilated 76
distal 1047
cancer see distal common bile duct carcinoma (DBDC)
functions 76
narrowing/strictures/stenosis endoscopic therapy 439, 491
inflammatory pancreatic head mass 366, 367
pancreatic cancer 718
obstruction, therapy 367, 444
stening 367, 439, 443, 443
stone 148
common channel 147
anatomy 11, 13, 27, 75, 76
gallstone obstruction 146–147, 149, 197
long (common channel syndrome) 11, 27
sphincter ampullae 75
common channel hypothesis, gallstone pancreatitis 146–147, 149, 197
common channel syndrome 11, 27
acute biliary pancreatitis 146–147, 149, 197
common hepatic artery 252
pancreatoduodenectomy 470, 471, 473
staging laparoscopy 767, 767
compartment syndrome theory chronic pancreatitis pain 350, 422
see also abdominal compartment syndrome (ACS)
computed tomography (CT)
acute biliary pancreatitis 296, 297
acute fluid collections 312
acute necrotic collection 242, 243, 243
acute pancreatitis
CT Severity Index (CTSI) 244–245
grading 238, 244–245
Japanese CT Severity Index 245
outcome 327
pediatric 225
ampullary carcinoma 1059, 1060
computed tomography (CT) (cont’d)
- anatomy of pancreas 12, 13
- autoimmune pancreatitis 411–412, 551, 551
- chronic pancreatitis
diagnosis 406, 407, 407
- differential diagnosis 411
- preoperative 469
- cone beam (CBCT), pancreatic cancer 891
- contrast-enhanced (CE-CT)
- accuracy limitations 245–246
- acute edematous pancreatitis 241, 241–242
- acute fluid collections 312
- acute necrotizing pancreatitis 242, 289
- avoidance in severe acute pancreatitis 260
- inflammatory pancreatic head mass 366, 367
- nephrotoxicity of contrast 247
- pancreatic cancer 724, 733–738, 740, 791
- metastatic disease 652
- size/morphology 569
- radiation dose 248
- dynamic, PanNETs 957, 968, 970
- groove pancreatitis 412–413
- insulinoma 1004, 1004
- IPMN 598
- jaundice work-up 1043, 1044
- lymphoepithelial cyst 595–596, 596
- mucinous cystic neoplasm 596, 597
- multidetector (MDCT) 407, 412
- metastatic disease 737–738
- pancreatic cancer 724, 733–738, 740, 741–742
- pancreatic cancer diagnosis 734, 734–735, 735, 755, 766, 771, 771
- pancreatic cancer staging 736, 736, 737, 771, 771, 777
- technique 733–734
- pancreatic cancer 771, 771
- 3D reconstructions 734
- screening test 747
- pancreatic fistulas 318
- pancreatic pseudocysts 593
- pancreatic swelling, delayed enhancement 523, 525, 551, 551
- pancreaticobiliary, protocols 733–734
- PanNETs 949, 950, 957, 968, 969
- perfusion
- acute necrotic collection 242, 243, 243, 244, 246
- radiation dose 248
- peripancreatic tumors 1039, 1039, 1042, 1042, 1043
- preoperative, in chronic pancreatitis 469
- spiral, peripancreal tumors 1042, 1042
- computed tomography (CT) scanners 734
- congenital anomalies 24–39, 213
- acute pancreatitis with 213–218, 221
- annular pancreas 25, 25–26, 215
- anomalous pancreaticobiliary ductal union 214, 214
- choledochal cysts see choledochal cyst
- ductal anomalies 27
- duplication cysts within pancreas 28, 215–216, 216
- ectopic pancreas 26–27, 27, 215
- isolated enzyme deficiencies 28–29
- Johanson–Blizzard syndrome 30, 30–31
- pancreas divisum 26, 26, 213, 214
- pancreatic agenesis 24–25
- pancreatic cysts 27–28, 28
- pancreatic hypoplasia 24–25
- Pearson marrow pancreas syndrome 30
- secretory insufficiency 28
- Shwachman–Diamond syndrome 29, 29–30
- congenital disorders, pancreatic endocrine function 31–32
- secretory insufficiency 28
- see also hereditary disorders
- congenital hyperinsulinism (CHI) 31
- congenitally short pancreas 25
- CONKO-001 trial 848, 848, 851, 851, 886, 896, 906, 908
- CONKO-005 trial 852
- continuous closed lavage, lesser sac 290, 291, 291
- corticosteroids, in autoimmune pancreatitis 529, 555, 556, 557
- relapse treatment 556–557, 560–561
- side-effects and managing 557–558
- type 2, response 536, 546, 547, 558
- corticotropin-releasing hormone (CRH) 956
- cost-effectiveness
- laparoscopic surgery 652
- treatment vs surveillance, cystic neoplasms 620–621
- COX-2 111
- COX-2 inhibitors 233, 880
- coxsackievirus B infection 232
- CPAI gene, mutation, pancreatic cancer 746
- CRAC Ca2+-selective channels 51, 53
- creatinine, serum, acute pancreatitis 207, 209, 262
- CRISPR/Cas system 1116
- critical illness, intestine driving 166
- CRS-207 859
- Cryptosporidium infections 80
- crystallloid fluid resuscitation, animal studies of acute pancreatitis 252–253
- CTFR gene see cystic fibrosis transmembrane conductance regulator (CFTR)
- CTLA-4 857–858
- CRISPR/Cas system 1116
- critical illness, intestine driving 166
- CRS-207 859
- Cryptosporidium infections 80
- crystalloid fluid resuscitation, animal studies of acute pancreatitis 252–253
- CTFR gene see cystic fibrosis transmembrane conductance regulator (CFTR)
- CTLA-4 857–858, 858, 860
- antibodies 860
- antibodies (ipilimumab) 858, 858, 860, 861
- CTRC see chymotrypsin C (CTRC)
- CTR gene, mutations see chymotrypsin C (CTRC)
- ctsb gene 180
- CTTNBI gene mutation 584
- Cushing syndrome 956, 1015
- CXCL4 71
- cyclic ADP-ribose (cADPR) 47, 47–48
- cyclic AMP (cAMP), in duct cell secretion 57, 58, 60
- cyclo-oxygenase 2 (COX-2) inhibitors 233, 880
cyclophosphamide (Cy)
- GVAX (whole-cell vaccine) 858–859, 861
- whole-cell vaccine with 858–859
- cyclophosphorine A 345
- cyst(s), pancreatic 567
- age and 568, 568
- asymptomatic 589, 618
- see also cystic neoplasms/tumors
- benign see cystic lesions, pancreatic (PCL), nonneoplastic
calcification 570
- classification 590
- clinical presentation 589
- congenital 27–28, 28
- diabetes and insulin use 569
- epidemiology 567–569, 568, 748
- ethnic and geographic factors 568–569
- gender and 568
- identified by screening 747–748
- low-risk, types 593
- lymphoepithelial, imaging 595–596, 596
- misclassification 580
- mucin producing 603–604
- see also intraductal papillary mucinous neoplasia (IPMN); mucinous cystic neoplasm (MCN)
multifocality, enucleation contraindication 634
- pancreatic cancer risk 419
- polycystic kidney disease with 32
- potential malignancy see cystic neoplasms/tumors
- risk factors 568–569
- size/morphology 569
- detected by screening 748
- enucleation contraindication 634
- surveillance 748
- treatment 440–442
- ablation 637–638, 638
- aspiration 637
- enucleation see under cystic neoplasms/tumors
- surgical resection 580
- unilocular/oligolocular 637
- von Hippel–Lindau syndrome 33
- see also pseudocysts, pancreatic
cyst gastrostomy see cystogastrostomy “cyst-in-cyst” appearance 574, 575, 596, 597, 710
cystadenoma
- acinar cell 578, 699
- serous see serous cystadenoma
cysteine protease cathespin B see cathespin B
cystic change, neuroendocrine tumors (CPNT) 567, 569, 570
- cystic duct, gallstone acute pancreatitis 151
- cystic fibrosis (CF) 28
- “atypical” 161
- CFT gene mutations 161, 391, 392, 393
- therapy targeting 60, 394
- chronic pancreatitis 393
- clinical features 392
- diabetes in 393
diagnosis 393
ductal secretion damage 60
gene therapy 394
genotyping 393
inheritance 398
lack of CFTR, effects 391
malignancy risks 392–393
organs affected by 391
recurrent acute pancreatitis 393, 398
Shwachman–Diamond syndrome vs 29
treatment 393–394
gene therapy 394
cystic fibrosis-related diabetes mellitus (CFRD) 393
cystic fibrosis transmembrane conductance regulator (CFTR) 57, 58, 59, 60, 160–161, 378
alcohol effect on 138, 345
bicarbonate excretion 160, 161
enzyme replacement 393
cysts, pancreatic; cystic fibrosis; imaging 593–596
cystic neoplasms/tumors 565–664, 589
ablution 637–638, 638
acification 569
automatic 618
abnormality of 620–621
quality of life 619
surveillance frequency 619
surveillance strategy 618
surveillance vs surgery 618, 619, 641
treatment algorithm 620
treatment guidelines 619, 620, 621
characteristics 590
cystic neoplasms 567, 574, 589,
590, 641
clinical presentation 589–592
cytological evaluation 603–610, 604
diagnosis 589, 632, 646, 721–722
enucleation 632–640, 645
contraindications 633–634, 634, 637
indications 632–633, 633
laroparoscopic 650–651
outcomes 635–637, 636, 645
pancreatic fistula 634, 635, 637, 645
patient selection 632–633, 637, 638
postoperative management 635
technique 634, 635
epidemiology 567–572, 569–570, 570, 573, 590, 641
epithelial 574
histologic classification 573–579
history 697, 697–698, 698, 698–699
imaging 593–602, 596–600, 628, 632, 724
invasive cancer after 567, 573, 580
clinical features 589
enucleation contraindication 633
resection 632
risk 618
long-term outcome 660–664
molecular mechanisms 580–588
cellular applications 584–585
gene mutations 582
implications for families 585
natural history 611–617, 661–663
nonneoplastic 574
noninvasive pseudocyst 440
pathology 696–699
recurrence, management 655–659
secondarily cystic 607
surgery 622–626, 641–648, 649, 749
alternative procedures 645
central pancreatectomy 642, 645
complications 641, 992
distal pancreatectomy 614, 642, 644
dPPHR 622, 623–624, 624, 624, 625, 992
dPPHR, subtotal head resection 623–624, 624, 625, 625
enucleation see above
laroparoscopic see laroparoscopic surgery
local pancreatic head
resection 622–623
middle segment resection see pancreatic
central segment resection (PMSR)
minimally invasive 645
cystic neoplasms, pancreatic 563–604
ablation 637–638, 638
acute pancreatitis in 569
asymptomatic 618
cost-effectiveness of 620–621
management 620–621
quality of life 619
surveillance frequency 619
surveillance strategy 618
surveillance vs surgery 618, 619, 641
treatment algorithm 620
treatment guidelines 619, 620, 621
characteristics 590
classification/types 567, 574, 589,
590, 641
clinical presentation 589–592
cytological evaluation 603–610, 604
diagnosis 589, 632, 646, 721–722
enucleation 632–640, 645
contraindications 633–634, 634, 637
indications 632–633, 633
laroparoscopic 650–651
outcomes 635–637, 636, 645
pancreatic fistula 634, 635, 637, 645
patient selection 632–633, 637, 638
postoperative management 635
technique 634, 635
epidemiology 567–572, 569–570, 570, 573, 590, 641
epithelial 574
histologic classification 573–579
history 697, 697–698, 698, 698–699
imaging 593–602, 596–600, 628, 632, 724
invasive cancer after 567, 573, 580
clinical features 589
enucleation contraindication 633
resection 632
risk 618
long-term outcome 660–664
molecular mechanisms 580–588
cellular applications 584–585
gene mutations 582
implications for families 585
natural history 611–617, 661–663
nonneoplastic 574
noninvasive pseudocyst 440
pathology 696–699
recurrence, management 655–659
secondarily cystic 607
surgery 622–626, 641–648, 649, 749
alternative procedures 645
central pancreatectomy 642, 645
complications 641, 992
distal pancreatectomy 614, 642, 644
dPPHR 622, 623–624, 624, 624, 625, 992
dPPHR, subtotal head resection 623–624, 624, 625, 625
enucleation see above
laroparoscopic see laroparoscopic surgery
local pancreatic head
resection 622–623
middle segment resection see pancreatic
central segment resection (PMSR)
minimally invasive 645
pancreatectomy 643–645
pancreatoduodenectomy 622–623, 643–644
parenchymal preservation methods 650, 651
postoperative management 645–646
preoperative evaluation 643
resection rationale and goals 622, 623, 632
surveillance vs 618, 619, 641
total pancreatectomy 642, 644
surveillance 660, 663, 748
asymptomatic neoplasms 618, 619, 641
IPMN see intraductal papillary mucinous
neoplasia (IPMN)
mucinous cystic neoplasm 642–643, 661
serous cystic neoplasms 660
see also specific types (as listed page 574)
cystic PanNETs (cPanNET) see pancreatic
neuroendocrine tumors (PanNET)
cystic teratoma, mature 578
cystinuria 34
cystogastrostomy
laroparoscopic 283, 308, 483, 484
laroparoscopic vs endoscopic 483
open 293
cytochrome c oxidase deficiency 34
cytochrome P450
carcinogen metabolism 673–674
CYP2A6 676
CYP2E1 137, 140
CYP2E1 gene variants 141
tropical chronic pancreatitis 386
cystohistology 603
cytokeratins, PanNETs 935
cytokine(s)
acute pancreatitis
pathogenesis 64, 67–68, 71
polymorphisms 162
severity assessment 208, 209
autoimmune pancreatitis, type 1 511, 511–512
autoimmune pancreatitis, type 2 513, 513
in inflammatory response 338
islet dysfunction, chronic pancreatitis 496
pancreatic stellate cell activation 107, 138
pancreatic stellate cells producing 107–108, 138
proinflammatory 162, 338
acinar cell injury 71–72, 252
substance P interactions 352
cytology
neoplasms 603–610, 604
pancreatic cancer 767, 767–768
PanNETs 933–934, 934, 935
D
d-Dimer, activated protein C decreasing 184
Dagradi-Serio-Iacono operation see
pancreatic middle segment resection
(PMSR)
damage-associated molecular pattern
molecules (DAMP) 242, 316
Index

dermoid cysts 578
diabetes mellitus 123
development 6
insulin-dependent (IDDM) 21, 22
see also diabetes mellitus
diseases
see also congenital anomalies
dexamethasone test 956

diabetes mellitus
acute pancreatitis complication 324, 325
doctrine 496
in autoimmune pancreatitis 496
in chronic pancreatitis 361, 399, 402, 431, 495
β-cell dysfunction 495, 496
hormone changes 495, 496
incidence 495, 496
pathogenesis 496–497
PSC role 110
risk factors 496
see also diabetes mellitus, type 3c
in cystic fibrosis 393
experimental models, pancreatic exocrine dysfunction 127–128
in hereditary pancreatitis 376, 377
hypertiglyceridemia 231
insulin-dependent (IDDM) 1121
long-standing, pancreatic cancer risk 668
in young (MODY) 938, 940, 943
pancreatic cancer relationship 667, 668, 720, 911
diabetes prior to cancer 717–718, 720
pancreatic cancer risk factor 667, 668, 720
reverse causality 911
pancreatic cystic lesions 569
pancreatic exocrine dysfunction 127, 495, 496–497
pancreato-duodenectomy
complication 622, 623, 911
PDX1 mutation 7
permanent neonatal (PNDM) 32
postoperative, after distal pancreatectomy 793, 911, 912
resection 911
total pancreatectomy, after 798–799
transient neonatal 31
in tropical chronic pancreatitis 385, 387
type 1 1121
islet transplantation see islet transplantation
pancreas transplant see transplantation
pancreatic pancreatic cancer risk factor 720
type 2 pancreas transplantation 1123
pancreatic cancer and 718, 720
type 3c (pancreatic/pancreatogenic) 361, 377, 431, 495, 911
clinical features 497
complications 498, 799
definition and prevalence 495
diagnosis 497, 499
enzyme replacement therapy 499
glycemic control, brittle diabetes 431, 497, 798–799
hypoglycemic agent therapy 498–499
insulin therapy 498, 499, 799
islet cell hormone response to meal 497, 498
after left pancreatectomy 793, 911, 912
after pancreatoduodenectomy 911, 912
prognosis 500
therapy 498–500
after total pancreatectomy 798–799
TPIAT 500
see also diabetes mellitus, in chronic pancreatitis
diabetic ketoacidosis 231, 262
diabetic neuropathy 498
diarrhea
chronic pancreatitis 399
isolated enzyme deficiencies 28
pancreatic cancer 717
total pancreatectomy, after 799
diazoxide 972, 1005
diet 426
acut pancreatitis management 254, 255
chronic pancreatitis management 430–431
fruit/vegetables, pancreatic cancer risk reduction 669
hereditary pancreatitis 377
pancreatic adaptive growth 99, 99–100
pancreatic cancer risk 669
pancreatic protein synthesis regulation 95–96
see also nutritional supplementation
dietary factors, alcohol-induced acute pancreatitis 138
digestion, of nutrients 426
digestive enzymes 10, 43, 426
acin cell secretion of 43, 196, 426
Ca2+–mediated control 51–52
CCK role 43, 44, 85–86
see also acinar cell(s), secretion; cholecystokinin (CCK) activation 43, 378, 426
cathepsin B role 180–181
see also protease(s), pancreatic; trypsinogen
amylase see amylase, pancreatic functions 426, 799
increased, chronic alcohol use effect 137, 344
insufficiency/failure to secrete see exocrine insufficiency
lipase see lipase, pancreatic
pancreatic growth and 95
proteases see protease(s), pancreatic recombinant 428
secretion see pancreatic secretion (process)
storage 64
synthesis 64, 95–98, 97
alcohol effect 344
see also protein synthesis, pancreatic
see also enzyme(s); exocrine pancreas; protease(s), pancreatic
digestive tube, primitive 3
dipeptidyl-peptidase-4 (DPP-4) inhibitors 234, 499
direct endoscopic necrosectomy (DEN), infected pancreatic necrosis 275, 278–279, 279, 280
 disconnected duct syndrome 302, 317–318
distal pancreatectomy in 475
stenting 319
disease-specific ligands 600
disseminated intravascular coagulation (DIC) 184
distal cholangiocarcinoma (bile duct carcinoma) 1049, 1051–1052, 1083
adjuvant therapy 1089–1090, 1091
ERCP 1041, 1041
frequency 1037, 1038
gene mutations 1051
long-term survival 1051, 1085, 1085, 1089–1090, 1097–1099, 1098
lymph node involvement 1083, 1084, 1099
neural plexus invasion 1086
 palliative therapy 1089, 1090, 1092
preinvasive neoplasms 1051–1052
prognostic factors 1051, 1084, 1084, 1086, 1099, 1099
recurrence 1099
superficial spreading 1086–1087
surgery 1083–1088
bile duct cut margin 1086–1087
complications 1087
hepatoduodenal ligament skeletonization 1086
lymph node dissection 1084–1085, 1086
pancreatoduodenectomy 1083, 1087
elastase-1
feecal see fecal elastase-1
serum 539
elastography, EUS, pancreatic cancer 728–729
electrocardiogram (ECG), acute pancreatitis 185, 185–187
electrolyte(s), duct cell secretion 57, 58
electrolyte management, acute pancreatitis 312–313
electroporation, irreversible 845, 876
electrocardiogram (ECG), acute pancreatitis
emergency department see acute pancreatitis, treatment (ICU)
endoctrine cell(s)
differentiation/development 5, 6
immunostaining 21, 21–22, 22
types and numbers 21–22
see also islets of Langerhans, cells; specific cell types
endoctrine function tests 402
endoctrine insufficiency
acute pancreatitis complications risk 324
autoimmune pancreatitis treatment, after 557, 562, 562
chronic pancreatitis see chronic pancreatitis
exocrine insufficiency with see exocrine insufficiency
isolated congenital 31–32
pancreatic calcification and 496
pancreatoduodenectomy, after 622, 623
endoctrine pancreas 10, 123
anatomy 20–21
genital disorders 31–32
dysfunction, acute pancreatitis
complication 324–325, 325, 328
fibrosis, pancreatic stellate cell role 110
functional reserve 24
histology 20–22, 21, 22
tumors see pancreatic neuroendocrine tumors (PanNET)
see also islets of Langerhans
endoctrine tumors, pancreatic see neuroendocrine tumors
dendtherm 3, 4, 4
mesoderm interaction 5
endoluminal ultrasound, gallstones investigation 151
endophlebitis 385
endoplasmic reticulum (ER)
Ca2+ release 46, 46, 50–51, 51
stress during acute pancreatitis 70–71, 98
alcohol effects 138
protein synthesis inhibition 98, 98
stress during chronic pancreatitis 336
unfolded proteins 70–71
endoscopic debridement
necrotizing pancreatitis 274, 274
pseudocysts/WON, after acute pancreatitis 301–302
endoscopic drainage
chronic pancreatitis pain 423
infected pancreatic necrosis 278–280, 279, 280–281
pancreatic fluid collections 313–314
pancreatic pseudocysts 440–441, 488
transmural 278–280, 279, 280–281
transspallay 278, 829
endoscopic necroscopy see necroscopy
endoscopic retrograde
cholangiopancreatography (ERCP)
acute biliary pancreatitis 152–153, 296, 297, 298–299
acute pancreatitis due to 150
NSAIDs role in preventing 251
ampullary tumors 1059–1060
benign 1069
annular pancreas 25, 25
autoimmune pancreatitis 526, 552, 552–553
balloon enteroscopy-assisted 836
common bile duct diameter 76
complications, pancreatitis 179–180
disconnected duct syndrome 302
gallstones investigation 151
pancreas divisum 26, 26
pancreatic cancer 771, 829, 835, 839
biliary decompression 829, 835
pancreatic fistula 318, 319
pancreatic neuroendocrine tumors 949
pancreatic pseudocysts drainage 442
pediatric acute pancreatitis 225
periampullary tumors 1041, 1041, 1041–1042
preoperative, in chronic pancreatitis 469
endoscopic retrograde pancreatography (ERP)
early chronic pancreatitis 371
secretin stimulation of exocrine function 401
endoscopic secretin test 401, 401, 406
endoscopic sphincterotomy (ES)
acute biliary pancreatitis treatment 152–153, 297
ampullary tumors 1060, 1071
pancreatic fistula 319
endoscopic stenting
indications 1042
main pancreatic duct 367
pancreatic cancer 772, 829, 830, 831, 836
palliative 839
periampullary tumors 1042
endoscopic therapy
ampullectomy, in ampullary carcinoma 1061
biliary pancreatitis see acute biliary pancreatitis (ABP)
chronic pancreatitis see chronic pancreatitis, treatment
common bile duct obstruction 444
common bile duct stenosis 439, 491
cyst gastroscopy 483
drainage see endoscopic drainage
dental stones 442–444, 443, 491
gastric outlet obstruction 439
infected pancreatic necrosis 277–282
adverse events 280–281
development and reasons for 278
dual-modality drainage 279
EUS-guided multi-gateway 279
goals 278
necroscopy 275, 278–279, 279, 280
results 280
sten placement 278, 279, 280
timing 272, 278, 283
transgastric access 278
transmural drainage 278–280, 279, 280–281
transmural entry devices 279
transspallay drainage 278
pancreatic cancer (PDAC) 772, 829
biliary decompression 829, 830, 831
pancreatic fistulas 318
papillectomy 1068, 1069–1072, 1070, 1075
pseudocysts/WON after acute pancreatitis drainage vs necroscopy 301–302
indications 301
endoscopic ultrasound (EUS)
course acute biliary pancreatitis 296, 297
acute fluid collections 312
ampullary adenoma 1069
ampullary carcinoma 1060, 1060–1061
celiac plexus blockade guided by 490
chronic pancreatitis diagnosis 371, 406
contrast-enhanced (CH-EUS)
IPMN 598
pancreatic cancer 728–729
cystic neoplasms, asymptomatic 619, 620
early chronic pancreatitis diagnosis 371
endoscopy, pancreatic cancer 729
equipment 728, 729, 731
fine-needle aspiration (FNA)
ampullary carcinoma 1060–1061, 1069
complications 730
contraindications 729
cystic neoplasms 603, 607, 619, 620
diagnostic yield/safety 729–730
equipment 731
factors affecting 731
nonfunctioning PanNET 968
pancreatic cancer 693, 729–730, 739, 771–772
PanNETs 949, 950, 951, 957, 971
fine-needle biopsy (EUS-FNB), ampullary carcinoma 1060
gastrojejunostomy guided by 837, 838
infected pancreatic necrosis treatment 279
insulinoma 957, 1004, 1005, 1020
IPMN 598, 598, 642
jaundice work-up 1043, 1044
lymphoepithelial cyst 595–596, 596
pancreatic cancer (PDAC) 693, 728–732, 771–772
advantages/disadvantages 729
celiac plexus neurolysis 838, 881
obstructive jaundice palliation 836
screening test 747
pancreatic intraepithelial neoplasms 748
pancreatic pseudocysts 593, 594
PanNETs 962, 1015–1016
pediatric acute pancreatitis 225
periampullary tumors 1040, 1040, 1042, 1043
preoperative, in chronic pancreatitis 469
Index
Index

extracellular matrix (ECM) 109
cell membrane interactions 109
hyaluronic acid, targeted therapy 868
turnover, stellate cell role 106, 112, 338
extracellular matrix (ECM) proteins
excess, fibrogenesis 106, 107
acute pancreatitis 109
removal, stellate cell role 109
pancreatic cancer progression and 120
synthesis, stellate cell role 106, 112
extracorporeal shock wave lithotripsy (ESWL) 423, 439–440, 442, 490
extrahepatic biliary tract see biliary tract, extrahepatic
extrapancreatic cancer, in autoimmune pancreatitis 563

Fajan’s index for insulinoma 949
familial adenomatous polyposis (FAP) 137, 140, 213, 343
acute pancreatitis 186
gene mutations 141
toxicity mechanisms 137, 138
fatty acid ethyl esters (FAEE) 137, 140, 213, 343
acinar secretion see acinar fluid
ductal, secretion see duct cell(s)
fluid collections see pancreatic fluid collections (PFC)
fluid resuscitation
aggressive, acute pancreatitis 251–254, 258, 312–313
animal studies 252–253
guidelines 253
human studies 253–254, 254, 312–313
monitoring 312–313
over-aggressive 253–254
pediatric 225
pre-transfer to ICU 260
rational for, and role of 252, 312
coолод 253, 313
crystalloid, acute pancreatitis 252–253
human studies 253, 254, 313
F18-fluoro-deoxyglucose PET see FDG-PET
5-fluorouracil (5-FU) 848, 850, 853
adjuvant, pancreatic cancer 848, 850, 853
radiation with 843, 847, 886, 887
advanced pancreatic cancer
first-line therapy 873, 874
second-line therapy 876
adverse reactions 874
ampullary carcinoma 1093
distal cholangiocarcinoma 1090
pancreatic cancer recurrence after 898
PanNETs 975, 1006
FOLFIRINOX regimen 773, 844, 852, 877
adjuvant therapy 852
advanced pancreatic cancer 874–875
first-line vs gemcitabine 875
adverse effects 875
downstaging borderline resectable disease 844, 844
drugs in 874
locally advanced pancreatic cancer 784, 785–786, 817, 824, 875, 876
FOLFIRINOX regimen 1093
follicular pancreatitis 517
fogeet 4
FOX1 gene mutations 25
FOX2 gene mutations 32
Frantz tumor see solid pseudopapillary neoplasm (SPN)
free fatty acids (FFA) 137, 186, 262
Frey procedure 367, 450, 451, 453, 454, 463–464, 491
as alternative to DPPHR 463–464, 492
laparoscopic 484–485, 485
long-term outcomes 450, 462, 492
outcome, Beger procedure vs 368, 491–492
fucosyltransferase 2 nonsecretor status (FUT2) 346
fungal infections
acute pancreatitis due to 232, 232
necrotizing pancreatitis complication 266
Index

Halsted, William Stewart 783

HbA1c 1110
islet transplantation and 1110, 1112, 1113
pancreatic cancer 770
total pancreatectomy, after 799
type 3c diabetes 497, 499
see also blood glucose
head of pancreas
anatomy 3, 10, 11
cancer 828, 1037
inflammatory pancreatic head mass vs 366–367
pancreatoduodenectomy 783
resectability status 777
CT image 12
cysts
surgery vs surveillance 619
see also cystic neoplasms/tumors
inflammatory mass see inflammatory pancreatic head mass (IPHM)
neural plexus, dissection 1086
as “pacemaker” of pain 450
resection
chronic pancreatitis 450–451, 454,
459, 491
for cystic neoplasms 622, 623
duodenum-preserving see duodenum-preserving pancreatic head resection (DPHPR)
of mass 450, 451
pancreatitis in pancreas divisum 213
in PanNETs 990–991, 991, 992
parenchyma-sparing (limited) 623
partial, Frey procedure see Frey procedure
procedures 450–451, 451, 491
pylorus-preserving 491
hedgehog pathway 5, 25
Helicobacter pylori 525, 540, 669, 954
hematocrit, acute pancreatitis 207, 209, 259
hemipancreatectomy
chronic pancreatitis 459
see also pancreatectomy, distal
ehemolytic uremic syndrome (HUS) 873–874
hemorrhage see bleeding
hemorrhagic shock, models 166
hemosuccus pancreaticus 451
hepatic artery
embolization 913
pancreatic cancer staging 773
PanNET invading 996, 996, 997
resection, pancreatic cancer 784–785
see also common hepatic artery
hepatic metastases see liver metastases
hepatic steatosis 799
hepatocholcecytosteinunostomy 829
hepaticogastrectomy, EUS-guided 837
hepatochojenunostomy 473, 474, 644, 829,
831–832
advanced pancreatic cancer 772
hepatitis B virus (HBV) 558
hepatitis E virus (HEV) 232
hepatocyte growth factor (HGF) 111
hepatocyte nuclear factor 1α (HNF1α) 7
hepatodudinal ligament, skeletonization 1086
hepatoid variant, PDAC 696
hepatomegaly, peripanillary tumors 1038
hereditary disorders
metabolic, affecting pancreas 33–35,
34, 398
pancreatic endocrine function 31–32
genetic susceptibility factors
see hereditary factors see genetic susceptibility factors
hereditary nonpolyposis colorectal cancer syndrome (HNPPC) 1074
hereditary pancreatic cancer see pancreatic cancer, familial
hereditary pancreatitis 35, 337, 374–383
acute pancreatitis in 375–376
age at onset of symptoms 375, 376
chronic pancreatitis development 374,
375, 376
clinical features 222, 375
definition 374
diabetes mellitus in 376, 377
differential diagnosis 374
epidemiology 374–375, 398
exocrine insufficiency 376, 377
gene mutations 377, 377–379,
379–380, 398
CFTR 374, 375, 378–379, 746
CTRC 378–379
PRSSI 159, 179, 180, 337, 374, 375,
377–378, 379, 746
PRSSI 122C 375
PRSSI 122H 141, 159, 180, 337,
375, 376
SPINK1 35, 179, 374, 378, 398, 746
genetic counseling 379–380
genetic testing 379–380, 402, 402
in children 380
genotype–phenotype correlations 378
inheritance patterns/penetrence 337,
374, 379
management 376–377, 451
molecular genetics 377–379
pancreatic cancer and 362, 376, 418–419,
669, 690
screening, imaging 419
surgical treatment 476
hernia, incisional 327
hindgut 4
histamine H2 antagonists 974
histology of pancreas (normal) 13–22
endocrine pancreas 20–22, 21, 22
exocrine pancreas 13–20, 17, 18, 19, 20
histones 336, 940
historical aspects 397
 MOUSE bindings 114
 acute biliary pancreatitis 146
 acute pancreatitis 178
alcohol-induced acute pancreatitis 135–136
chronic pancreatitis 397
IPMN 707
pancreatic ductal adenocarcinoma 679
pancreatic middle segment resection 627
pancreatoduodenectomy 783
transplantation, pancreatic 1121–1122
H/K⁺-ATPase pump (ATP12A) 57, 58
HRA antigens
autoimmune pancreatitis, type 1 510
sensitization, islet transplant 1114
homocystinuria 34
Honolulu Consensus 521
hormones
pancreatic growth regulation 98, 99, 99–100
pancreatic secretion control see pancreatic secretion (process) see also specific hormones
human equilibrative nucleoside transporter 1 (hENT1) 764, 852–853, 875
human genome 679, 865
human immunodeficiency virus (HIV) 80, 232
hyaluronic acid 868
hyaluronidase 868
hydromorphone 260
3-hydroxy-3-methylglutaryl-CoA reductase inhibitors 234
3-hydroxykynurenine 168, 170
25-hydroxyvitamin D 429, 430
hyperalgesia 352
hypercalcemia
hyperglycemia
hyperinsulinism
hyperlipidemia 33, 231
hypertriglyceridemia
hypertriglyceridemia-induced pancreatitis 230–231
hypocalcemia, acute pancreatitis 186–187
hypoglycemia
Beckwith–Wiedemann syndrome 33
hyperinsulinemic, persistent, of infancy 31
impaired awareness (IAH) 1110, 1122
insulin-induced, pancreatic secretion stimulation 88
insulinoma 946–948, 947–948, 948, 954, 1002
diagnostic criteria 1002, 1003
islet transplantation recipient selection 1110
pancreatic transplant indication 1122
risk in diabetes in chronic pancreatitis 431, 497, 498, 500
in hereditary pancreatitis 376
severe episodes (SHE) 1110, 1122
hypoglycemic drugs 400, 498–499
hypokalemia, ECG in 185
hypomagnesemia, acute pancreatitis 186–187
hypoperfusion, acute pancreatitis 258, 260
hypotension 261
hypothyroidism, neonatal diabetes with 32
hypovolemia 185, 258
hypoxia, acute pancreatitis 181
hypoxia-induced factor (HIF) pathway 581, 940, 942
i
idiopathic acute pancreatitis 150, 151, 213, 222
idiopathic chronic pancreatitis see chronic pancreatitis, idiopathic
idiopathic duct-centric pancreatitis (IDCP) 505, 520, 534, 550, 555
see also autoimmune pancreatitis (AIP), type 2
IgG4 see under immunoglobulin G (IgG)
IgG4-related sclerosing disease (IgG4-RD) 530, 539, 540, 550, 555, 556
Ihh gene 25
ileus 168
imaging see specific diseases and imaging modalities
immune cells, in chronic pancreatitis 337, 337–338
immune complex, autoimmune pancreatitis relapse 546, 546–547
immune system 856–858, 857
adaptive 856–858, 857
innate 67, 117, 856
nervous system crosstalk 351, 352
pancreatic cancer 856–858, 857
immunoglobulin A (IgA), autoimmune pancreatitis 545
immunoglobulin G (IgG)
Fab-arm exchange 512
IgG1, type 1 autoimmune pancreatitis 510–511, 513
IgG4 512, 513, 544
elevated levels, diseases 540, 544
IL-4 and IL-10 role 511
IgG4, in type 1 AIP 505, 510–511, 512–513, 516–517, 520, 530
immunostaining 516–517
levels, disease activity 525
as marker for diagnosis, levels 524–525, 540, 541, 544, 545
as marker for differential diagnosis 545–546
as marker for relapse prediction 546, 546–547
pancreatic cancer vs 546
IgG4-related sclerosing disease (IgG4-RD) 530, 539, 540, 550, 555, 556
immunoglobulin M (IgM), autoimmune pancreatitis 545
immunomodulators
autoimmune pancreatitis therapy 556, 557, 558
non-vaccine, pancreatic cancer 860
pancreatic cancer 844–845
side-effects 558
immunotherapy, pancreatic cancer see pancreatic cancer
Imrie, Clement 205
inborn errors of metabolism 33–35, 34, 221
incidentaloma 982
incisional hernia 913
incretins 497
mimetics 234, 499
Indian hedgehog (Ihh) 25
indomethacin, rectal 251
infants, persistent hyperinsulinemic hypoglycemia 31
infected pancreatic necrosis see necrosis, in acute pancreatitis
infectious diseases
acute pancreatitis complication 265–266
acute pancreatitis due to 231–232, 232
pediatric acute pancreatitis 221
inferior vena cava 12
inflammation
neurogenic see neurogenic inflammation
pancreatic see pancreatitis
pancreatic cancer 417, 857, 879
perineural, chronic pancreatitis 350, 351
systemic see systemic inflammation
inflammatory bowel disease (IBD) 234, 535
type 2 autoimmune pancreatitis 513, 521, 526, 535
inflammatory cells, acinar cell injury 71–72, 252
inflammatory mediators/molecules
pancreatic cancer 857
release, sensory afferents in pancreas 175
release in acinar cell injury 71–72, 252
inflammatory pancreatic head mass (IPHM) 365–370
clinical workup 366–367
differential diagnosis 366–367
histopathology 368
inflammatory pancreatic head mass (IPHM) (cont’d)
    imaging 366, 367, 412, 454
    incidence 365
as “pacemaker” of pancreatitis 365
pathophysiology 365–366
symptoms and clinical problems 365–366
    treatment 367–368, 451, 453
inflammatory (pseudo) tumor see inflammatory pancreatic head mass (IPHM)
inflammatory response/pathways 334, 338
acute pancreatitis 67–68, 71, 252
autoimmune pancreatitis 512–513
chronic pancreatitis 337, 337–338
    coagulation, interactions 184
cytokine polymorphisms and 162
cytokine release 338
regulation 162
sentinel acute pancreatitis event model 334, 335
inherited disorders see hereditary disorders
injury–wound cycle 334–336,
    insulin 1,4,5‐trisphosphate (IP3) 46, 49
    injury–wound cycle 334–336,
inherited disorders see hereditary disorders
independence, after islet functions 24
insulin 4
    carbohydrate in diet, effect on amylase receptors 49
    regeneration 100, 101
    translation initiation PI3K–PKB–mTORC1 pathway 96, 97
    regeneration of pancreas 100, 101
    resistance, troglitazone reducing 128
    secretagogues, type 3c diabetes 499
    receptors 49
    in inherited disorders 32
    pancreatic cystic lesions 569
    total pancreatectomy, after 799
    type 1 diabetes 1121
    type 3c diabetes 498, 499
    translation initiation PI3K–PKB–mTORC1 pathway 96, 97
    insulin growth factor-1 receptor (IGFR) 868
    insulin-like growth factor-1 (IGF-1) 101
    insulin-promoter factor-1 (IPF1) gene 24
    insulinoma 989, 1002–1008, 1019–1021
    adherence to pancreatic duct 983
    clinical features 718, 719, 947–948, 948, 1002, 1003, 1019
diagnosis 949, 954, 1002–1003, 1020
    gene mutations 938
    hypoglycemia 946–948, 948, 954, 1002, 1003, 1005
    incidence 1002
    investigations 1002–1003, 1020
    EUS 957, 1004, 1005, 1020
    fasting test 949, 954, 1003, 1003, 1020
    imaging 1003–1005, 1004, 1020
    instrumental/invasive 957, 1005
    mixed-meal tolerance test 1003
    nuclear imaging 1005
    serum-based laboratory 954, 955, 1002–1003
    localization 1003–1005, 1004, 1020
    long-term outcome 1032
    malignant 1032
    in MEN1 954, 962–963, 1002, 1005, 1020, 1021
    secondary, in MENI 1032
    size and malignancy 1019
    surgical treatment 963, 983–984, 1005–1006, 1020, 1021, 1032
    glucose management 1020–1021
    laparoscopic 1021
    treatment 1005–1006
    chemotherapy 1006
    medical 964, 972–973, 973, 1005
    “insulin–pancreatic acinar axis” 123
    insulin–acinar portal system 124, 124
    insulin–acinar relationship 123–124
    islet/exocrine pancreas structural relationship 123–124
    islet hormones regulating exocrine secretion 84–94, 124–127
    see also pancreatic secretion (process)
    intensive care unit (ICU) 511–512
    in acute pancreatitis see acute pancreatitis, treatment (ICU)
    interferon therapy, rare PanNETs 1016
    interferon γ (IFNγ) 118, 511
    interleukin-4 (IL-4) receptor signaling, blockade, fibrosis inhibition 119–120
    in type 1 autoimmune pancreatitis 511, 511, 512
    interleukin-6 (IL-6)
    activated protein C decreasing 184
    acute pancreatitis severity assessment 208, 209
    pancreatic cancer cells producing 112
    interleukin-8 (IL-8) 162
    acute pancreatitis severity assessment 159, 208, 209
    gene polymorphisms 162
    release, substance P role 352
    type 2 autoimmune pancreatitis 515, 513
    ulcerative colitis 513
    interleukin-10 (IL-10), type 1 autoimmune pancreatitis 511, 511, 512
    interlobular ducts 16, 18
    necrosis 196, 196
    interlobular fibrosis 195
    International Association of Pancreatology (IAP) 619, 620, 655, 657
interstitial edematous pancreatitis see under acute pancreatitis
interstitial tissue 20, 20
interventional radiology (IVR), obstructive jaundice 836–837
intestinal-type adenocarcinoma 1050, 1050, 1059
intestinal villi, ischemic injury 167
intestine
    driving critical illness 166
    dysfunction in acute pancreatitis 167–168, 168
    injury, acute pancreatitis severity 167–168, 168
    ischemic injury 167
    MODS see multiple organ dysfunction syndrome (MODS)
    permeability increase, acute pancreatitis 183–184
    role in severe acute pancreatitis 167–168, 168
    intra-abdominal pressure 205, 261, 262, 313
    intra-ampullary biliary tract neoplasms (IPNB) 1047, 1049, 1052
    intra-ampullary papillary tubular neoplasms (IAPN) 1047–1048
    carcinomas associated 1049, 1049, 1051
dysplasia 1048
    histology 1048, 1048
    immunophenotype 1048
    intraductal neoplasms 709
    IPMN see intraductal papillary mucinous neoplasia (IPMN)
    ITPN see intraductal tubulopapillary neoplasms (ITPN)
    intraductal oncocytic papillary neoplasm (IOPN) 698, 707
    "fish-eye/fish-mouth" papilla 596, 707
    intraductal papillary mucinous neoplasia (IPMN) 575–577, 581, 583, 641, 696, 707–709
    acute pancreatitis in 327
    age at diagnosis 570, 612–613, 707
    asymptomatic 604, 707
    biomarkers 683
    branch-duct (BD-IPMN) 570, 576, 591, 596, 598, 614, 642, 707
    age and risk factors 570, 707
    characteristics 611, 707
    communicating ducts 634
    enucleation 632, 633, 635
    histology 662
    malignant, enucleation contraindication 633
    malignant, growth rate 618
    MRCP 632, 633
    natural history 612, 612, 661
    pathology 696–697
    quality of life 619
    resection, indications 633
    surgery 642, 661
    surveillance vs surgery 618, 619, 620
    time-dependent progression 613
    characteristics 590, 591, 611, 642
islet transplantation (cont’d) autotransplant see total pancreatectomy with islet cell autotransplantation (TPIAT) immunosuppression 1110, 1112, 1113 adverse effects 1114–1115 neoplasms after 1115 research priorities 1115–1116 unlimited islet cell supply, generation 1116 xenotransplantation 1116 “islet–acinar axis” 123 see also insulo–acinar relationship islet–acinar blood supply 22 islets of Langerhans 3, 10, 123 blood supply 22, 124, 124 cells congenital hyperinsulinism 31 differentiation 123 hyperplasia 31, 1019 number per islet 123 stem-cell derived, transplantation 1116 turnover and division 98 types 3, 123 see also endocrine cell(s); specific cell types in chronic pancreatitis 496, 497 congenital absence 32 decay, after severe acute pancreatitis 324 histology 17 hormones regulation of exocrine secretion 124–127 response to meal, diabetes 497, 498 see also specific hormones hyperplasia 31 immunostaining 21, 21–22, 22 innervation 123 macrophages in 119 number 21, 123 reduced, chronic pancreatitis 496 secretory granules 22, 22 size and shape 20–21 structural relationship with exocrine pancreas 123–124 in tail vs head of pancreas 21 ultrastructure 20–21, 22 see also endocrine pancreas isomylase, newborn levels 222 isolated congenital endocrine insuficiency 31–32 isolated pancreatic enzyme deficiencies 28–29, 29 isovaleric acidemia 34 Izbicki pain score 422, 422

magnetic resonance imaging (MRI) (cont’d)
pancreatic cancer 412, 724, 738–741, 740, 741, 771
diagnosis 755
lesion identification 739–740, 740
screening test 747
staging 740–741
pancreatic pseudocysts 593
PanNETs 949, 950, 957, 968
peripancreatic tumors 1039
PET-MRI, pancreatic cancer 758, 758–759, 759
secretin-stimulated, chronic
pancreatitis 401
serous cystic neoplasm 594, 594–595
T1-weighted image 739–740, 740, 742
T2-weighted image 739–740, 741
technique 738
main pancreatic duct (MPD) see pancreatic duct(s), main
major histocompatibility complex (MHC) 856, 857, 860
malabsorption 426
chronic pancreatitis 399, 431
tropical chronic pancreatitis 386
maldigestion 426
malnutrition
chronic pancreatitis 429
inflammatory pancreatic head mass 366, 367
total pancreatectomy, after 799
tropical chronic pancreatitis 385–386
manometry, sphincter of Oddi motility 78, 78, 80
MAPK pathway 101, 581
maple syrup urine disease 34
marginal ulcers 910, 910
Marseille classification, chronic pancreatitis 371
Marshall Score, acute pancreatitis 205, 206, 209
matrix metalloproteinases (MMPs) 72, 338
mature cystic teratoma 578
maturity-onset diabetes of the young (MODY) 7, 32
McCune-Albright syndrome 585, 707
MCP-1 gene 158, 159, 162
MCP-1 - 2518A/G 162
Meckel syndrome 33
median arcuate ligament (MAL) syndrome 644
mediastinitis 318
medullary carcinoma 681, 682, 695
ampulla of Vater 1051
MEK inhibition 867
MEK pathway 867
MELAS/MERRF 34
membrane capacitance 52
MEN1 gene 942, 961–962
mutations 938, 939, 940, 961–962, 1019
see also multiple endocrine neoplasia type 1 (MEN1)
6-mercaptopurine, acute pancreatitis and 234
mesenchyme, stromal cells 3
mesenteric abscess 274
mesenteric lymph in acute pancreatitis composition change 168
experimental pancreatitis 168, 169
toxicity 169, 169
translating into treatment 169–170
drainage 167
MODS see multiple organ dysfunction syndrome (MODS)
organ failure due to 166
mesenteric thrombosis 317
mesentericopapillary axis, PanNET invasion 996, 996
mesoderm 3, 4, 5
mesopancreas 778, 779, 823
mesothelin anti-mesothelin vaccines 683
overexpression 682, 683, 859, 910
mesotrypsin 179
metabolic diseases acute pancreatitis associated 230–231
affecting pancreas 32–33
inherited 33–35, 34
metamizole 423
metaplasia, ductal epithelium 19
metastases see liver metastases; lymph node metastases
metastatic disease, in pancreatic cancer see pancreatic cancer
metformin 400, 498–499, 675
methylene, in chronic pancreatitis pain 436
methylmalonic acidemia 34
methylthioadenosine phosphorylase (MTAP) 683
Mezir, James J. 911
microadenoma 934, 989
microcirculation, pancreatic, acute pancreatitis 251–252
microthiasis, acute biliary pancreatitis 151, 151
micronutrient deficiency chronic pancreatitis 429
tropical pancreatitis 385, 386
supplementation, chronic pancreatitis 430
miRNA
acute pancreatitis 168
dysregulation, in IPMN 583
high-grade dysplasia 682
mucinous cystic neoplasm 584
pancreatic cancer/PDAC 682, 764, 771
PanNETs 957
solid pseudopapillary neoplasms 584
microsatellite instability
acinar cell carcinoma 683
ampullary carcinoma 1075
ductal adenocarcinoma 681
medullary carcinoma 695
microvilli 15, 16
midgut 4
Mikulicz disease 527, 530
Milwaukee classification, sphincter of Oddi disorders 79–80, 80
minimal access retroperitoneal pancreatic necrosectomy (MARPN) 283–285, 284, 285
minimally invasive surgery 804
cystic neoplasms 645
left pancreatectomy, in cancer 792–793, 793
necrotizing pancreatitis see necrotizing pancreatitis, acute
see also laparoscopic surgery (pancreatic); robotic surgery
minimally invasive therapy, pancreatic fluid collections 313–314
miR-21 764
Mitchell-Riley syndrome 25
mitochondria
acinar cells 15, 17, 46–47
Ca2+ overload 53
dysfunction, acute pancreatitis 70, 167
mitochondrial disorder, Pearson syndrome 30
mitochondrial DNA, mutations, pancreatic cancer 682
mitochondrial permeability transition pore (MPTP) 53
mitomycin C 1090, 1093
mitotic count, PanNETs 925, 926, 927, 928, 930, 989
mixed adenoneuroendocrine carcinoma (MANEC) 930
mixed anti-inflammatory response syndrome (MARS) 178
mixed-meal tolerance test 1003
mixed neuroendocrine-nonneuroendocrine neoplasm (MiNEN) 930, 933
models of pancreatitis see experimental pancreatitis
monocyte(s) 117, 118
monocyte chemoattractant protein-1 (MCP-1) 158, 162
Morgagni, Jean-Baptista 397
MPACT trial 852
mRNA 96, 100
MTAP gene 680, 683
mTOR pathway 585, 876, 938, 940–941, 943, 967
complex 1 (mTORC1) 940–941, 942, 943
pancreatic growth 99, 100
pancreatic protein synthesis 96, 98
inhibitor see everolimus
MUC1
ampullary carcinoma 1050
IPMN 576, 613, 698, 709
mucinous cystic neoplasm 575
pancreatic cancer prognosis 910
pancreatic intraepithelial neoplasms 706
MUC2
ampullary neoplasms 1048, 1050, 1059
cystic neoplasms 575, 709
MUC4 674, 675
MUC5AC
ampullary carcinomas 1050
intraductal tubulopapillary neoplasms 710, 1052
IPMN 576, 613, 698, 709
mucinous cystic neoplasms 575
pancreatic intraepithelial neoplasms 706
MUC2
intraductal tubulopapillary neoplasms 710, 1052
IPMN 576, 613, 698, 709
pancreatic intraepithelial neoplasms 706
mucin
in bile, acute pancreatitis 151
IPMN 591, 603, 605, 606, 642, 695
mucinous cystic neoplasms 574, 603, 605, 606, 698, 710
pancreatic intraepithelial neoplasms 705–706
mucin-producing cysts see intraductal papillary mucinous neoplasia (IPMN);
mucinous cystic neoplasm (MCN)
mucinous carcinoma, ampulla of Vater 1051
mucinous cystic neoplasm (MCN) 567, 574–575, 641, 642, 698–699, 710–711
age at diagnosis 570, 574, 590, 614, 642, 710
asymptomatic 604
calcification 574, 596, 614
characteristics 590, 590, 642
clinical presentations 590–591, 710
“cyst-in-cyst” appearance 574, 575, 596, 597, 710
cytology 603, 604, 605, 606
diagnosis 440, 596
epidemiology 569, 570, 574, 590, 614, 642, 710
genome mutations 582, 584, 585, 683, 711, 941
high-grade/low-grade 574–575, 710, 711
histology 574–575, 575, 614, 698, 698–699
imaging 596, 597, 600
immunohistology 575, 711
invasive carcinoma in 570, 573, 575, 614, 642, 699, 710–711
macroscopic appearance 574, 575, 614 “minimally invasive” 575, 661
misdiagnosis 591
molecular mechanisms 584, 711
natural history 614, 642
ovarian-like stroma (OS) 574, 575, 575, 614, 698, 710
pathology 573, 574–575, 596, 698–699, 710, 710–711
as precursor for pancreatic cancer 682, 683, 710–711
prognosis/survival 575, 614, 642, 661, 671, 710
staging 575
surgery 614, 642, 661
enucleation 632, 633
indications 642–643
laparoscopic 649
long-term outcome 661, 710
resection, indications 633, 642–643, 661
surveillance after 614, 642–643, 661
unilocular cyst 574, 596, 597
mucinous metaplasia 706
mucinous noncystic carcinoma see colloid (mucinous) carcinoma
mucous cell hyperthropy 706
Muir–Torre syndrome 1058
multidisciplinary team
infected pancreatic necrosis management 277
pancreatic cancer resection 790
multidrug resistance 266
multiorgan failure, post-necrosectomy in necrotizing pancreatitis 286
multiple endocrine neoplasia type 1 (MEN1) 933–934, 942, 1019
chemotherapy 964
epidemiology 961
genetics 923, 942, 961–962
pancreatic lesions, histology 934, 942
PanNETs 923, 933–934, 937, 942, 961–966, 969, 989
ATRX/DAXX and MENI genes 941, 942
clinical features 963
cystic (CPANET) 570, 591
diagnosis 962, 962–963
enucleation 984, 985
follow-up 964, 965
frequency 922, 961, 962
functional types 954, 961, 963
gastrina 961, 962, 963, 973–974, 1022
insulinoma 954, 962–963, 1002, 1005, 1020, 1021
medical treatment 964
metastatic 963, 964
nonfunctioning types 963, 994, 1022, 1031
prognosis 964–965, 969
surgical treatment 963–964, 969, 1021 “three-P triad” 961
tumors in 933–934, 961
see also MENI gene
multiple endocrine neoplasia type 4 (MEN4) 1019
multiple organ dysfunction syndrome (MODS) 166, 178, 181, 205, 252
altered gut–lymph composition 168
gut–lymph toxicity 168
in acute pancreatitis 204
intestinal role 166–167, 167–168
mesenteric lymph role 166–167, 168–169
prognosis, acute pancreatitis severity 204
multiple organ failure see multiple organ dysfunction syndrome (MODS)
muscarinic receptors 86
mutations see specific genes
Myb transcription factor 118
myeloid-derived suppressor cells (MDSC) 857
myofibroblast-like cell see pancreatic stellate cell (PSC), activation
myofibroblasts 18, 19
n Na+/K+ pump 52, 56, 57
Na+/HCO3− cotransporter 160
Na+/K+2Cl− cotransporter 52, 56
NAdam, Ca2+ releasing messenger 49–50
nab-paclitaxel, pancreatic cancer 786, 852, 874
nafamostat 170
L-NAMe 87
NAP52 study 342–343
narcotic dependence 466, 468–469
nasal potential difference (NPD) 393
nasal wings, aplasia 30, 30
nasocystic lavage, infected pancreatic necrosis 278
nasogastric feeding, acute pancreatitis 254–255, 313
nasojugal feeding
acute pancreatitis 254–255, 313
chronic pancreatitis 431
nasopancreatic stenting, preoperative 635
National Comprehensive Cancer Network (NCCN) 728, 757, 768, 777, 814, 887, 898, 968
navitoclax 867
neck of pancreas 10, 11, 12
serious cystadenoma 628
necrosectomy 289, 306
endoscopic 307
direct, infected pancreatic necrosis 275, 278–279, 279, 280
fistula formation after 317
loss of tissue, dysfunction correlated 324
minimal access complications 286, 287
laparoscopic transperitoneal 283
necrotizing pancreatitis 274, 278, 283–288
outcome 287
percutaneous retroperitoneal 283
postoperative course 286–287
retroperitoneal (MARPN) 283–285, 284, 285
techniques 283–285, 284, 285, 286–286
video-assisted retroperitoneal 285, 307
open surgical see under necrotizing pancreatitis
necrosis, in acute pancreatitis 178, 193, 277
acute necrotic collection 195, 242–243, 243, 266, 277, 311
acute peripancreatic fluid collection 195, 242, 266, 277, 311
acute renal failure and 183
Atlanta classification 266, 272
debridement see under necrotizing pancreatitis, acute
definition 277, 311
diagnosis 241
by CT 238, 242, 243, 245, 277, 289
early, need for 248
overestimation by CT 289
radiologic 242–244, 243, 244, 245, 246, 311
diagnostic criteria, accuracy 239
ductal 194, 196, 196
erly, diagnosis 245–247
endoscopy see endoscopic therapy
histopathological patterns 193, 194, 311

Index
Index

pancreatic buds, development 4–5
isolated left-sided 451
left see pancreatoduodenectomy, distal
PanNETs, nonfunctioning 968
parenchymal-sparing 645, 655
laparoscopic 651
partial 649
complications, salvage surgery after 797
conversion to total (TP) 801
IPMN 642
lesions identified by screening 749
proximal 469
contraindications 467
robotically assisted 652
distal 652, 792–793, 810, 810–811, 811
salvage completion 797
indications 801
perioperative outcomes 798
segmental, IPMN 642
spleen preservation with 644, 650, 791
total see total pancreatectomy (TP)
see also pancreatic resections
pancreatic abscesses 241, 302, 305, 316, 318, 441
pancreatic adenocarcinoma see pancreatic ductal adenocarcinoma (PDAC)
pancreatic agenesis 24–25
pancreatic amylase see amylase, pancreatic
pancreatic anastomotic strictures 911
pancreatic ascites 168, 318, 366, 451
pancreatic atrophy 735, 736
pancreatic buds, development 4–5
pancreatic cancer 665–917
in autoimmune pancreatitis 517, 553, 557, 563
biomarkers see pancreatic cancer, tumor markers
biopsy 776
liquid, tumor profiling 869
body of pancreas 828
left pancreatectomy see pancreatectomy, distal
resectability status 777
staging and resection eligibility 790
borderline resectable 773, 777, 783, 791, 814
characteristics 773, 777, 814, 843
downstaging by neoadjuvant therapy 783, 843–844, 844
emerging recognition 843
evaluation, staging 736, 757, 773, 773, 777
pancreatoduodenectomy 783
proton beam therapy 888–891, 889, 890
radiotherapy 887–888
resectability criteria 784, 791
bypass surgery see pancreatic cancer, palliative surgical bypass
carcinogenesis 673–674
clinical studies 675, 676
experimental studies 673–675, 675
signaling pathways 673, 674
cell proliferation/migration factors inducing 111–112
PSC role 111
chemoradiotherapy see chemoradiotherapy
carcinogenesis, fibrotic stroma role 112
chemotherapy 683, 768, 773
adjuvant see pancreatic cancer, adjuvant therapy
neoadjuvant see pancreatic cancer, neoadjuvant therapy
palliative see pancreatic cancer, palliative chemotherapy
personalized, marker for 764
in chronic pancreatitis see chronic pancreatitis
classification 757
clinical history 717–719
diabetes mellitus 717–718
functional impairment 717–718, 719
nerve plexus invasion 718, 719
neuroendocrine see pancreatic neuroendocrine tumors (PanNET)
pain 717, 718, 838
symptoms 717, 718, 719, 828–829, 872
symptoms at onset of pancreatitis 418
tumor cell ingrowth 718, 719
colloid carcinoma 695
cone beam CT 891
cystic see cystic neoplasms/tumors
development from head to body/tail 778
diabetes relationship 667, 668, 717–718
diagnosis 127, 766, 770
CA19-9 and 762
NCCN guidelines 728, 757, 768, 777, 814
radiologic see pancreatic cancer, imaging
treatment indication 776
use of molecular markers 683
differential diagnosis
autoimmune pancreatitis 419, 546, 550, 552
chronic pancreatitis 367, 411, 451, 756
ductal see pancreatic ductal adenocarcinoma (PDAC)
edoscopic management 772
epidemiology 667–672, 835
familial 688–692
age at diagnosis 688
cancer risk in relatives 688, 745
common genetic variants 690, 746
definition 688, 745
gene mutations 688, 689–690, 745, 746
low-penetration genes 746
pathology 688–689
predisposition genes 689–690, 746
screening 745–746
surveillance 748
total pancreatectomy 800
treatment 689
family history
IPMN recurrence risk 656, 657
pancreatic cyst lesions risk 569
as risk factor 670, 688, 721, 745–746
benefits 679, 745, 746, 852
as prognostic factors 910
see also under pancreatic ductal adenocarcinoma (PDAC)
head of pancreas see head of pancreas
hereditary pancreatitis see hereditary pancreatitis
lgG4 levels 545
imaging 724–725, 728, 733–744, 771, 824
contrast-enhanced CT 734, 734–735, 735, 815, 824
CT see computed tomography (CT)
EUS see endoscopic ultrasound (EUS)
EUS-elastography 729
EUS-FNA see under endoscopic ultrasound (EUS)
FDG-PET see FDG-PET
intraoperative ultrasound (IOUS) 824
MDCT 733–738, 739, 740, 766, 771
MRCP 771
MRI 412, 738–741, 739, 740, 755, 771
PET see positron emission tomography (PET)
PET-CT 755, 756
PET-MRI 758, 758–759, 759
screening test 747
secondary signs of malignancy 735, 735, 736
surveillance by 748
immunology 856–858, 857
immunomodulator therapy 844–845
immunotherapy 683, 852, 856–864
antigen-specific vaccines 859–860
checkpoint inhibitors 858, 858, 859, 860, 861
combination 861
neotanget-based vaccines 860
non-vaccine immunomodulators 860
response, criteria 860
tumor-associated macrophage 861
vaccines with chemotherapy 858–859
whole-cell vaccines 858–859, 860
incidence 667
inflammatory state 857, 879
intraoperative radiotherapy 824
in IPMN 576–577, 642, 661, 682, 683
laparoscopy 766–767, 767, 772
diagnostic 766
pancreatoduodenectomy 804–805
staging 766
liver metastases 780
CT 738, 739
FDG-PET 757, 757
MRI 740, 740–741
surgery contraindication 814
total pancreatectomy vs pancreatoduodenectomy 800
local disease, survival trends 909, 909
local invasion 778, 823
local recurrence 898, 900, 901, 903
chemoradiation 901–903
patient selection for therapy 903
re-resection 899, 901, 903
survival 903
treatment 901
local vs metastatic, ratio 766
locally advanced (LAPC) 773, 773, 783, 784, 832
ablative therapy 872, 875–876
chemoradiation 876
chemotherapy 872, 873
first-line chemotherapy 875–876
FOLFIRINOX regimen 784, 785–786, 817, 824, 875, 876
locoregional treatment strategies 872, 875–876
neoadjuvant therapy 783, 784, 875–876, 844
palliative surgery 825
posterior artery-first approach 824
proton beam therapy 888–891, 889, 890
radiotherapy 887–888
resections, long-term outcome 785–786
resections, short-term outcome 783, 784
lymph node metastases 693, 790, 815, 898, 910
CT 737–738
dissection 779
lymphadenectomy 815
MRI 740
recurrence 900
medical treatment 842–917
metastatic disease 766, 772, 823, 898
chemotherapy 872, 873, 874–875
clinical features 770
CT 737–738, 739
detection 899
distant, survival trend 909, 909
distant metastases 738, 739, 780, 847
limited, surgery 814
liver see above
lymph nodes see above
management 872
metastasectomy 901
MRI 740–741
nicotine stimulating 674
pain 879
peritoneal see below
recurrence 895
resection 818
sites 737–738
SMAD4 gene loss 876
surgery 779–780, 818
unresectable cancer 777
see also pancreatic cancer, advanced
micrometastases 842, 847, 876, 895, 901
microRNA 682, 764, 771
migration of tumor cells, nicotine 674
mixed tumors (endocrine/exocrine) 681, 683, 686, 832
metastatic disease 766, 772, 823, 898
local recurrence 898, 900, 901
metastatic vs local locally advanced (LAPC) 773, 772
lymph node metastases 859
surveillance by 748
local recurrence 899, 901, 903
chemoradiation 901–903
patient selection for therapy 903
re-resection 899, 901, 903
survival 903
treatment 901
pain (long-term/late) 910–913
anastomotic strictures 911
diabetes (type 3c) 668, 911
exocrine insufficiency 911
anastomotic strictures 911
diabetes in newly diagnosed, diabetes in 668
anastomotic strictures 911
neoadjuvant therapy 773, 823, 828
aims 828
anticancer therapy 839
balloon enteroscopy-assisted ERCP 836
double stenting (duodenal/biliary) 837–838
duodenal metal stent placement 837
endoscopic 772, 829, 830, 831, 835–841
endoscopic biliary decompression 829, 835, 836
endoscopic ultrasound 836
ERCP 829, 835–836, 839
EUS-celiac plexus neurolysis 838
gastric decompression 831
of gastric outlet obstruction 837–838
interventional radiology (IVR) 836–837
neoadjuvant therapy 825
obstructive jaundice palliation 835–837
pain management 838–839
pancreatoduodenectomy 823–827
percutaneous celiac plexus neurolysis 838–839
PTBD 836
pancreatitis relationship 669
pathology 693–704
acinar cell lesions 699–701, 700
cystic neoplasms 696–699
ductal adenocarcinoma see pancreatic ductal adenocarcinoma (PDAC) as prognostic factor 909–910
locally advanced cancer 783, 784, 785–786, 844, 888
prognosis after 785
proton beam therapy 889
rationale 842
regimens 786, 843, 844, 888
resectable pancreatic cancer 842–843
stereotactic radiotherapy 888
survival after 907
nerve plexus invasion 718, 778, 779, 879
newly diagnosed, diabetes in 668
palliative therapy 839, 872–878
first-line 873–874
locally advanced carcinoma 875–876
recent advances 874–875
second-line 876–877
in systemic recurrence 899, 901
palliative surgical bypass 823, 825, 828–834, 835
diagnostic vs 829, 831
gastric bypass 831
neoadjuvant therapy 825
no bypass 831
multimodal therapy before 824
procedure choice 831–832
neoadjuvant therapy 825
obstructive jaundice palliation 835–837
pain management 838–839
pancreateoduodenectomy 823–827
percutaneous celiac plexus neurolysis 838–839
PTBD 836
pancreatitis relationship 669
pathology 693–704
acinar cell lesions 699–701, 700
cystic neoplasms 696–699
ductal adenocarcinoma see pancreatic ductal adenocarcinoma (PDAC) as prognostic factor 909–910
pancreatic cancer (cont'd)
  peritoneal metastases 738, 739, 766, 768, 779–780
  laparoscopy 766
  peritoneal cytology and 767, 767–768, 779–780
  personalized medicine 683, 852
  genetic alterations 683, 689, 868–869
  markers for 764, 852–853, 875
  precancerous lesions 705–716, 748, 750
  see also specific precursors
  prognosis 667, 693, 717, 776, 783, 847
  CA19-9 levels 762
  see also pancreatic cancer, survival
  prognostic factors 906, 909–910
  after pancreatectoduodenectomy 785
  peritoneal cytology 768
  progression
  PSC role 112
  time interval for 748
  proteomic study 763–764
  proton beam therapy (PBT) 888–891, 889, 890
  PSC interactions (bidirectional) 111
  radiotherapy see radiotherapy
  recurrence
  biomarkers 903
  incidence, timing, pattern 895–898, 896–897, 901, 906–907
  late 908
  local see pancreatic cancer, local recurrence
  PET and PET-CT 757–758
  PSC role 111
  risk factors 895
  recurrence, management 895–905, 899
  chemoradiation 899
  chemoradiotherapy 901–903, 902
  chemotherapy 899, 901
  local ablative therapy 899
  metastasectomy 901
  neoadjuvant therapy 898, 901
  surgery 899, 901, 903
  total pancreatectomy for 801
  regional disease, survival trends 909, 909
  in remnant pancreas, total pancreatectomy 801
  resectability 757, 773, 773, 783, 784, 814
  CT determining 736
  status, criteria 777, 791
  vessels determining 736, 823
  resection see pancreatic cancer, surgical resection
  response to therapy
  molecular genetics 683–684
  PET and PET-CT 757–758
  PET-MRI 759, 759
  risk
  allergies reducing 669–670
  in chronic pancreatitis 361–362, 417–419, 419, 669
  in hereditary pancreatitis 376, 418–419, 669
  pancreatic cysts and 419
  in tropical chronic pancreatitis 387
  risk factors 719–721, 721
  alcohol intake 668–669, 720–721
  body mass index 667, 668, 720
  carcinogen metabolizing enzymes 676
  chronic pancreatitis 417–420, 669, 720–721, 746
  diabetes 667, 668, 720
  dietary 669
  environmental 721, 721
  family history 670, 688, 721, 745–746
  gastrointestinal microbiome 669
  gene mutations 670
  hereditary pancreatitis 376, 418–419, 669
  obesity 667, 668, 720
  periodontal disease 669
  smoking 667–668, 673–678, 675, 719–720
  see also smoking
  screening 745
  age to start/end 747
  blood markers 749
  BRCA2 or BRCA1 gene carriers 746
  guidelines 747, 747
  imaging 747
  improved tests, development 749
  lesions identified by 747–748
  long-term outcome after 750
  pathology not detected by 748
  results 748
  surgery for lesions 749
  tests 747, 771
  stage I, 5-year survival 750
  staging 693, 696, 725, 824
  advanced PDAC 772–773, 773
  CT 736, 736, 737, 777
  downstaging by neoadjuvant therapy 842, 843
  laparoscopy 766, 825
  MRI 740–741
  PET and PET-CT role 756–757, 757
  MRI 758, 758–759, 759, 760
  preoperative 767, 777
  resection indication 776, 777
  TNM 772–773, 773
  supportive care 872
  surgical resection 777–778, 790, 814, 823, 842, 847
  bypass surgery 772
  clinical criteria 776, 790, 814
  clinical volume, outcome 780
  contraindications 814
  curative intent 783, 847
  cure rates 907, 908, 908
  distal pancreatectomy see pancreatectomy
  extrapancreatic nerve plexus invasion 778, 778
  indications 776–782, 790, 814
  “isolated” pancreatectomy 777
  laparoscopic see laparoscopic surgery
  late complications 910, 910–913, 912
  left pancreatectomy see pancreatectomy, distal
  for lesions identified by screening 749
  for local invasion 778
  for local recurrence 899, 901, 903
  lymph node metastases 779, 815, 819
  margin status, novel classification 824–825
  median survival and mean survival 907
  mesopancreas 778, 779
  mortality 776
  after neoadjuvant therapy 842–843, 907
  outcomes 667, 828, 895, 910–913
  palliative, bypass see pancreatic cancer, palliative surgical bypass
  palliative resections 823, 825
  pancreatectoduodenectomy see pancreatectoduodenectomy
  perioperative multimodal therapy 824
  peritoneal metastases 779–780
  posterior artery-first approach 824
  preoperative biliary drainage 835
  preoperative therapy see pancreatic cancer, neoadjuvant therapy
  R factor (residual disease status) 842
  R0 825, 842, 843
  R1 status 824–825, 842, 843
  R2 conversion to R1 825
  recurrence incidence/timing after 895–898, 896–897
  robotic see robotic surgery
  smoking after, decreased survival 676
  surgical criteria 777, 814
  surveillance after 898–899, 900, 901
  survival after 785, 898, 906–909
  survival rates (5-/10-year) 907, 908
  total pancreatectomy 778, 797, 800
  under-staged, management 825
  for vascular invasion 778–779, 815–817, 823, 824
  surgical resection, extended radical 814–822, 847
  arterial resections 816–817, 817
  combined vascular resections 818
  definition 814
  lymphadenectomy 815, 819
  metastases resection 779, 818
  multivisceral 818
  postoperative outcome 818–819
  procedures and outcomes 815–818
  quality of life after 819
  vascular resections 815–817, 823
  venous resections 815–816, 816
  surveillance 748, 898–899, 901
  after surgical resection 898–899, 900, 901
  survival 667, 693, 783, 847, 895, 906–917
  after adjuvant chemotherapy 906–907
  AJCC TNM staging 772–773, 773
  long-term, rates 908
  R1 resections 842, 843
  after resection 785, 898, 906–909
  after resection after neoadjuvant therapy 907
  selection bias in trials 907
  stage IV, extended surgery and 818
  after total pancreatectomy 800
trends over time 908–909, 909
see also pancreatic cancer, prognosis
tail of pancreas 828
CT imaging 791
left pancreatoduodenectomy see pancreatoduodenectomy
resectability status 777
staging and resection eligibility 790
targeted therapy 865–871
EGFR inhibition 867–868
enabling, mutation detection 868–869
IGFR 868
MEK/ERK inhibition 867
pancreatic stroma approaches 868
RAS, and KRAS 867
vulnerabilities in molecular
subtypes 865–867
treatment target, pancreatic stellate
cells 112
tubular complexes 14
tumor markers 762–765, 776, 866–867,
891, 901
adrenomedullin 127
CA19-9 762, 763, 770–771, 776, 844,
903, 906, 910
DU-PAN-2 763, 776
novel markers 763, 763–764
personalized medicine 764,
852–853, 875
as prognostic factors 910
SPan-1 763, 776
tumor microenvironment (TME) 856,
857, 859
in uncinate process 724–727, 777
unresectable 773, 777, 791, 814, 835
characteristics 814
CT determining 736, 824
pain management 880
resection after neoadjuvant
therapy 824
vascular invasion 694, 695, 778–779, 814
downstaging by neoadjuvant
therapy 843
local recurrence 900
see also pancreatic ductal adenocarcinoma
(PDAC)
pancreatic cyst(s) see cyst(s), pancreatic
pancreatic cystic lesions (PCL) see cystic
lesions, pancreatic (PCL)
pancreatic cystic neoplasms (PCN) see cystic
neoplasms/tumors
pancreatic diabetes see diabetes mellitus,
type 3c
pancreatic duct(s) 16
accessory see accessory pancreatic duct
(duct of Santorini)
anatomy 11, 11–12, 16, 75, 76, 1047
anomalous pancreaticobiliary ductal
union 214, 214
“cancerization” 694, 695, 706
chronic pancreatitis 407, 453–454
pathogenesis 345
common channel 11, 11, 13, 27, 75, 76
congenital anomalies 27
development 4, 5, 6, 24, 724, 725
eyard 4–5, 5
dilated 214
abrupt cut-off 735, 736
inflammatory pancreatic head
mass 367
IPMN 611
pancreatic cancer 735, 735, 736, 739
disconnected, syndrome 302, 317–318
stenting 319
dorsal 724, 725
duodenal content reflux 147–148
endoscopic drainage 423, 458
functions 56
hypertension, acute pancreatitis
due to 148–149
imaging, in autoimmune pancreatitis
552–553
in inflammatory pancreatic head
mass 365, 366
injury, autoimmune pancreatitis
type 2 516
integrity of system 18
large, alcohol-induced acute
pancreatitis 135–136
main (MPD) 16
“common channel” with bile duct 11,
11, 75, 76
cyst proximity to, enucleation 634
decompression, in IPHM 367
dilation 367, 611
drainage, in IPHM 367, 368
diagnosis 694
endoscopic drainage 367, 611
dilation 367, 611
endoscopically 367, 611
importance of system 18
injury in cyst enucleation 635
narrowing, type 1 AIP 522, 523–524,
526, 552, 552
serous cystadenoma 594
structure, endoscopic therapy 439
obstruction
acute pancreatitis model 63, 64, 148
ERCP stent placement 839
pancreatic cancer 739, 839
secondary, causes 149
therapy 443
two-phase hypothesis, acute
pancreatitis 149
perfusion, acute pancreatitis model 63, 64
small, protein plugs 136, 344
sphincters 75
stenosis/narrowing
autoimmune pancreatitis 526, 528, 534
outcome of therapy 491
therapy 442–444, 458
stening 297, 443–444, 458, 839
ampullary tumors 1071
stones
removal/fragmentation 439–440
surgical therapy 449–450
therapy 442–444, 443
strictures
endoscopic therapy 439, 490
therapy 443, 490
surgical drainage 455, 459, 491–492
indications 449–450, 453–454
outcome 490, 491–492
procedures 453–457, 454–455,
491–492
“small duct disease” 455
ultrastructure 16, 18–20
ventral 214, 724, 725
walls 17, 18
see also ductal system
pancreatic ductal adenocarcinoma
(PDAC) 1037
aberrantly differentiated endocrine
exocrine (ADEX) 866
adenosquamous carcinoma 694
advanced see pancreatic cancer, advanced
chemotherapy 683, 768, 773
circulating tumor DNA (ctDNA) 683–684
clinical features 726, 770, 772
colloid carcinoma 695
definition 693
diagnosis 693
diagnostic approach 772
evaluation
endoscopic 771–772
radiologic 771, 771
serologic 770–771
fibrotic stroma 868
cromoendocrine 17
macrophage role 117, 120
PSC role 111, 111–112
genetic alterations 577, 679, 683, 745, 746,
859, 860, 865
BRCA mutation signature 865–866
expression changes 682, 683, 694
historical aspects 679
homologous deletions 679
identifying, for targeted therapy
868–869
immunotherapy and 859, 860
less prevalent mutations (“hills”) 577,
679, 680, 681, 746, 865
major mutations (“mountains”) 679,
680, 680–681, 746, 865
mitochondrial 682
PanNET genetics vs PanNET
personalized therapy and 683, 689,
868–869
RNA splicing 866
subtypes 865–866
grading 693, 694
histology 693–694
desmoplastic stroma 694, 695, 868
perineural invasion 694, 695
variants 694–696
vascular invasion 694, 695
IPMN vs IPMN
IPMN associated 576
IPMN recurrence and 656
large duct variant 694
macrophage burden, prognosis and 120
medullary carcinoma 695
metastatic see pancreatic cancer
mixed acinar/ductal adenocarcinoma 701
mixed differentiation 696
pancreatic ductal adenocarcinoma (PDAC) (cont’d)
molecular mechanisms 679–866
chromosome instability 679, 681, 865
clinical applications 683–684, 747
DNA methylation changes 682
DNA repair defect 681, 683, 747, 865
locally rearranged subtype 866
microRNA 682
microsatellite instability 681
precursor lesions 682, 683
signaling pathways 866
subtypes, therapeutic vulnerability 865–867
MSI-high (microsatellite instability) 681, 683
pathology 693–696
gross pathology 693, 694
localization 693
personalized therapy see under pancreatic cancer poorly-differentiated 694
precursor/precancerous lesions 682, 683, 705–716, 748, 750
precursor lesions 682, 683
signaling pathways 866
subtypes, therapeutic vulnerability 865–867
pancreatic exocrine system see exocrine pancreas
pancreatic exocrine deficiency see exocrine insufficiency
pancreatic exocrine system see exocrine pancreas
pancreatic fibrosis see fibrosis, pancreatic
pancreatic fistula 286, 316–322
amylase level (drain) 645
classification 317–318
closure/healing 318, 320
colonic 317, 320
complications 316
cyst excision 645
management 635
risk/risk factors 634, 635, 637
definition 316
diagnosis 318
external 316, 317, 320
diagnosis/imaging 318
failure to heal 318
management 318–320
necrosis 319
nutrition 319
surgery 318, 319–320
timing of surgery 320
incidence 317
internal 316, 317, 319
diagnosis 318, 319
management 320
middle segment resection complication 630
moribund 635
pathogenesis 316–317
postoperative (POPF) 317, 635, 645, 649–650
diagnosis/symptoms 793
laparoscopic surgery 649, 650, 651
left pancreatectomy 793
management 793
pancreatoduodenectomy 785, 785, 990
surgery for PanNETs 990
total pancreatectomy 801
simple or complex 317
pancreatic fluid collections (PFC) 277, 305–306
acute 311
conservative management 312–314
imaging 312
minimally invasive drainage 313–314
acute necrotic see acute necrotic collection (ANC)
acute peripancreatic see acute peripancreatic fluid collection (APFC)
chronic pancreatitis 440
conservative treatment 312–314
encapsulated see walled-off necrosis (WON) management 311–315
post-acute 301
endoscopic drainage vs necrosectomy 301–302
endoscopic therapy 301–304
surgical therapy 305–310
pseudocysts see pseudocysts, pancreatic recurrence, risk factors 302
time frame 311
pancreatic function tests 406
chronic pancreatitis 400–401, 401
direct/indirect 401
noninvasive 401–402, 402
pancreatic head see head of pancreas
pancreatic hypoplasia 98, 99
pancreatic hypertrophy 98, 100
pancreatic incidentaloma 982
pancreatic injury
acinar-to-ductal metaplasia 338
acute, fluid collections 277
IgG4 and IgG1 causing 510
immune cell activation 337, 337–338
repeated, chronic pancreatitis 334–336, 335
response to 333
wound-healing responses 334
pancreatic intraepithelial neoplasms (PanIN) 682, 705–706
in autoimmune pancreatitis 517
classification/progression 705–706, 706, 748
clinical features 705
foam gland type 706
genetic alterations 683, 706
intestinal type 706
IPMN relationship 705, 706, 707
not detected by imaging 748
oncocytic type 706
PanIN-3 706, 706, 748
screening tests 749
pathology 705–706
prevalence in familial pancreatic cancer 688
PSC activation 111, 112
surgical resections 749
pancreatic islets see islets of Langerhans pancreatic juice carcinogens (smoking) 676
composition 43
leakage 316
disconnected duct syndrome 302, 317–318
pancreatic fistulas 317
post-laparoscopic surgery 650
postoperative, management 645
markers, autoimmune pancreatitis 541
in peritoneal cavity 318
reflux, common channel syndrome 27
secretin-stimulated 84, 125, 401, 409, 541, 562
IPMN detection 585, 596, 683
pancreatic cancer screening 749
secretion by acinar cells see acinar cell(s);
pancreatic secretion (process) stasis 197
volume (daily) 84
pancreatic lipase see lipase, pancreatic pancreatic lipase-related protein 2 427
pancreatic middle segment resection (PMSR) 627–631
complications 627, 630, 992
contraindications 627, 628, 629
cystic neoplasms 627, 992
historical aspects 627
indications 627
minimally invasive 627, 630
PanNETs 991, 991–992, 992
pancreatic neuroendocrine tumors (PanNET) 923, 926, 930, 931, 931, 1019
classification and grading 926, 927, 930 931
chemotherapy 975, 976, 1006
cytology 607, 608
imaging 599, 600
diagnosis 949–951, 994
rare PanNETs 1015–1016
time before/to 948
differential diagnosis 934–936
clinical features 947–948, 948, 949–951, 994–951, 994
radiofrequency ablation 980–981
surgery 998, 1031
radiotherapy 980, 981, 1031
surgical debulking 980, 981, 1031
TAE/TACE treatment 979–980, 980
localization 949, 1015–1016
gastrinoma 1009–1010, 1021
insulinoma 1003–1005, 1004, 1020
locally advanced metastases 998
surgery 995, 995–998, 996, 998
long-term outcome 1015, 1029–1034
lymph node metastases 986, 989, 995, 1016
frequency 984, 989, 1031
prognosis 1031
surgery 633, 986, 995, 1031
major, in PanNETs 994–1001
medical treatment 970, 972–978
algorithm 975, 977
angio genesis inhibitors 976
chemotherapy 964, 975–976
everolimus 941, 943
molecular-targeted agents 976, 976
radiouclides 959, 977
rare PanNETs 1016–1017
of secretory syndromes 972–974
selection, factors in 973
somatostatin analogs 964, 972, 974–975
targeting tumor growth 974–976
metastases 994–995
ALT in lesion, biomarker 942, 943
distant 998
imaging 950
liver see above
lymph node see above
mixed tumors (endocrine/exocrine) 930
molecular genetics 937–946, 967
ARX/DAXX genes/pathway 938, 940, 941, 943
chromosomal changes 938
clinical implications 943
comparison with other tumors 941–942
MEN1 pathway/MEN1 mutations 938, 940, 943
methylation profiles 943
mTOR pathway 938, 940–941, 943
pathways changed 938, 940–941
mortality 1030
nonfunctional 949, 953, 967–971, 972, 989, 994, 1013, 1022, 1030
clinical features 948, 967–968, 994, 1022
cystic changes 968
definition 967
diagnosis 955, 968, 969, 970, 1022
enucleation 984, 986
liver metastases 969–970, 1022, 1031
localized tumors 1030–1031
locally advanced, surgery 995, 995–998, 996
long-term outcome 989–990, 995, 1029–1031

Index
pancreatic neuroendocrine tumors
(PanNET) (cont'd)
lymph node metastases 984, 986, 995, 1031
malignant, surgery 990
medical treatment 971, 973, 975
in MEN1 963–964, 994, 1022, 1031
metastatic, multidisciplinary treatment 969–971, 1031–1032
metastatic, surgery 963, 994, 998, 1031
multifocal, surgery 1031
observation vs surgery 982, 989–990, 990, 1030
pathology 967, 968
preoperative imaging 1022, 1023
radionuclide imaging 958–959
small, sporadic, surgery 982, 1022
surgery indications 990
surgical treatment 963–964, 968–969, 970, 975–998, 1022, 1029–1031
treatment summary 970, 971
malignant tumors 931–932
unifocal, surgery 1030–1031
widespread disease, management 1031–1032
oncocytic variant 932, 933
pathology 930–936
G1 and G2 NET 931–932, 932, 933, 967
G3 NET 932, 967
macroscopic 930–931, 932
microscopy 931–934, 933–934
nonfunctional PanNETs 967, 968
peptide receptors 957, 959
pleomorphic variant 932, 933–934
poorly differentiated see pancreatic neuroendocrine carcinoma (PanNEC) 
prognosis 937
prognostic factors 990, 995
ATRX/DAXX mutations 943
rare 1013–1016, 1014, 1019
clinical features 1013, 1014
diagnosis 1015
imaging 1015–1016
localization 1015–1016
medical treatment 1016–1017
prognosis and survival 1015
surgical treatment 1016
risk stratification 1029–1030
somatostatin receptor (SSTR)
overexpression 957–958
somatostatin-secreting see somatostatinoma
sporadic, genetics 937–938
staging 925–927, 1029
TNM 925, 926, 926, 927, 930, 931, 1029, 1030
UICC/AJCC/WHO TNM 1029
surgical treatment 972, 982–1018, 1030–1032
arterial resection 996, 996
DPHHR 990–991, 991, 991
enucleation see above
functional tumors 963–964, 1005–1006
 gastrinoma 963, 990, 1010, 1022
 indications 989, 990
 insulinoma 963, 983–984, 1005, 1020, 1021
 laparoscopic 1021
 locally advanced nonfunctioning 995, 995–998, 996
 major resection 994–1001
 metastases, cytoreductive 1016
 metastatic nonfunctioning tumor 998
 middle-segment resection 991, 991–992
 nonfunctional tumors 963–964, 968–969, 970, 1022
 pancreatic head resection 990–991, 991, 991
 parenchyma-sparing local resection 990
 preoperative imaging 982–983
 surveillance vs 982, 989–990, 990
 workup for major resection 994–995, 995
 survival 937
 metastatic tumors 1031
 recurrence-free 1030
 therapeutic targets
 mTOR pathway 941, 943, 1016
 see also everolimus
 transformation to neuroendocrine carcinoma 933
 treatment, summary 970
 tumorigenesis routes 940, 942, 967
 in uncinate process 991, 996
 surgery 991
 VIP-secreting see VIPoma
 well-differentiated 923, 926, 931, 931–932, 934, 937, 941
 pancreatic polypeptide (PP) 400
 cells secreting 88, 123, 126
 decreased, in chronic pancreatitis 497
 development 6
 immunostaining 21, 21
 deficiency, diabetes in chronic pancreatitis 497
 measurement, chronic pancreatitis 400
 pancreatic secretion inhibition/reduction 88–89
 pancreatic protease see protease(s), pancreatic
 pancreatic pseudocyst see pseudocysts, pancreatic
 pancreatic resections
 complications 468, 465
 cystic neoplasms 642, 643, 645
distal 469, 475–476
 extended 814
 see also under pancreatic cancer
 head of pancreas see head of pancreas
 Kausch–Whipple see pancreaticoduodenectomy, classic
 laparoscopic see laparoscopic surgery (pancreatic)
 major, in chronic pancreatitis 450–451, 459, 467–478
 contraindications 467–469, 468
 indications 467, 468
 laparoscopic 479, 482
 pancreatectomy see pancreatectomy
 pancreaticoduodenectomy see pancreaticoduodenectomy
 preoperative investigations 469
 procedure types 469
 middle segment see pancreatic middle segment resection (PMSR)
 pancreatic cancer see pancreatic cancer
 pancreatic cysts, high-risk patients 749
 PanNETs see pancreatic neuroendocrine tumors (PanNET)
 proximal 469
 see also pancreaticoduodenectomy, classic pylorus-preserving 492
 total see total pancreatectomy types 469
 see also pancreatectomy
 pancreatic secretion (process) 84–94
 by acinar cells see acinar cell(s)
cigarette smoke (nicotine) effect 676
 in diabetes mellitus 127, 128
 experimental models 127–128
 by ductal cells see duct cell(s)
 feedback regulation 89–90
 inhibition/reduction 88–89
 adrenomedullin 127
 amylin 126
 anti-insulin infusion 125, 125
 enteroglucagon 89
 exogenous insulin 124–125
galanin 126–127
ghrelin 126
glucagon 89, 125
 glucagon-like peptide 1 (GLP-1) 89
 hyperglycemia 125
 other peptides 89
 pancreastatin 126
 pancreatic polypeptide (PP) 88, 126
 peptide YY 89, 126
 sites and mechanisms of action 86, 86
 somatostatin 89, 125–126
 neurohormonal/hormonal control 84–94, 123, 124–127
 feedback regulation 89–90
 see also inhibition (above); stimulation (below)
 postprandial 85–86, 87
 regulation by islet hormones 84–94, 123, 124–127
 stimulation/increased 84–88
 bombesin 87
 CCK 85, 85–86, 86, 88, 127
 ghrelin 87, 126
 insulin 87, 124, 125, 127
 neural mechanisms 88
 neuregulin 87
 nitric oxide 87
 secretin 84–85
 serotonin 86, 87
 sites and mechanisms of action 86, 86
 synergistic by CCK and 5-HT 87
pancreatic secretion(s) see digestive enzymes; pancreatic juice
pancreatic secretory trypsin inhibitor (PSTI) 160, 178, 398
see also SPINK1 gene
pancreatic stellate cell (PSC) 20, 20, 43, 106–109
activated, characteristics 107, 108, 338
activation 107–109
by alcohol 138
animal studies 110
chronic pancreatitis 109–110, 335, 337, 338
factors causing 107, 108, 110, 111, 138
markers 107, 108, 109
in pancreatic cancer 111, 112
in pancreatic injury 110, 335, 338
in tropical chronic pancreatitis 385
alcohol, direct effects on 136, 136, 138
alcohol metabolism 137
apoptosis 109
chronic pancreatitis etiology 106–107, 108–109
fibrolysis role 109
as progenitor cells 107
characteristics
non-activated (quiescent) state 106, 108
regenerative 109, 338
in health/normal 110
macrophage interaction 118, 119, 120, 338
morphology, and markers 106, 107, 107
non-activated (quiescent) state 106, 108
characteristics 108
numbers, increased 110
proliferation, acute pancreatitis 109
regulation, aberrant in chronic pancreatitis 338
signaling pathways 108, 108–109, 112
therapeutic targeting 112, 868
pancreatic stone protein (PSP) 127
pancreatic transplantation see transplantation, pancreatic
pancreatic triglyceride lipase, deficiency 29
pancreatic tumors
benign cystic see cystic neoplasms/tumors
endocrine see pancreatic neuroendocrine tumors (PanNET)
exocrine see pancreatic cancer
pancreaticobiliary maljunction see common channel syndrome
pancreaticobiliary reflex 27
pancreaticoduodenal arteries 252
pancreaticoduodenectomy see pancreaticoduodenectomy
pancreaticogastrostomy 651
pancreaticojejunostomy 472, 474
chronic pancreatitis 470, 472, 474
duct-to-mucosa 644
invagination method 644
laparoscopic 483, 651
laparoscopic pancreaticoduodenectomy 805
lateral 449
chronic pancreatitis 470, 483, 490
outcomes 490
laterolateral 449, 450
longitudinal 491
in middle segment resection 629
mucosa-to-mucosa, chronic pancreatitis 472, 474
pancreatic cancer 785
techniques 644
telescopic 629
pancreatitis 173
acute see acute pancreatitis
alcoholic see alcoholic pancreatitis
autoimmune see autoimmune pancreatitis (AIP)
chronic see chronic pancreatitis
ductal fluid secretion defects 60
gallstone see acute biliary pancreatitis (ABP)
hereditary see hereditary pancreatitis
nicotine role 674
pancreatic cancer relationship 669
paraduodenal see groove (duodenal)
pancreatobiliary-type adenocarcinoma 1050
pancreatoblastoma 700
in Beckwith–Wiedemann syndrome 33
genetic alterations 683
histology/pathology 700, 701
surgical resection 701
pancreaticoduodenectomy 469, 473, 643–644
anatomic considerations 644
in chronic pancreatitis 469–475
laparoscopic 482
laparoscopic vs open surgery 482
long-term results 470, 473–475, 474, 476, 477, 491
patient selection 469–470
perioperative outcomes 470, 473, 475
technique 470–473, 472, 473
classic (Whipple) 459, 491, 643–644, 804, 824, 1042
ampullary carcinoma 1061, 1062, 1067, 1077, 1078
chronic pancreatitis pain management 424
complications in pancreatic cancer 785, 785, 910–911
laparoscopic technique vs 805, 807
long-term outcome in pancreatic cancer 785–787
PanNETs 990
short-term outcome in pancreatic cancer 783–785
survival after, pancreatic cancer 785
complications 622, 623, 645–646, 785, 910–911
anastomotic strictures 911
diabetes mellitus (type 3c) 622, 623, 911
exocrine insufficiency 622, 623, 911–912, 912
nonalcoholic fatty liver disease 912–913
in pancreatic cancer 785, 785, 910, 910–911
type 3c diabetes 911, 912
cystic neoplasms 622–623, 643–644
complications 645–646
IPMN 642
laparoscopic 651
diabetes mellitus after 622, 623
distal cholangiocarcinoma 1083, 1087
DPHR vs 463, 491–492, 622–623
duodenal cancer 1081
historical aspects 783
“isolated”, in pancreatic cancer 777
laparoscopic 651, 804, 806
learning curve 811
open surgery vs 805, 807
outcomes 805
pancreatic cancer 804–805, 807
patient selection and indications 804
technique 804–805
minimally invasive 787, 804
modifications 469–470
mortality 622, 783
palliative 823–827
pancreatic cancer (PDAC) 776, 777, 824
factors affecting outcome 784–785, 786–787
laparoscopic 804–805, 807
long-term outcome 785–787, 786, 805, 910–913
lymphadenectomy in 815
margin status, novel classification 824–825
margins 693
robotic surgery 804, 805–808, 809
short-term outcome 783–785, 785
total pancreatectomy vs 800
PanNETs 990
peripancreatic cancer 1061, 1062, 1077, 1078, 1097
pyloric resection, distal cholangiocarcinoma 1083
pylorus-preserving 644
distal cholangiocarcinoma 1083–1084
pancreatic cancer 778
pancreatic cancer, long-term outcome 785–787, 910
pancreatic cancer, short-term outcome 783–785
radical, inflammatory pancreatic head mass 367, 368
robotic (RPD) 804, 806
learning curve 811
outcomes 806, 808
pancreatic cancer 804, 805–808, 809
pancreatoduodenectomy (cont’d)
patient selection and indications 804
port configuration 805, 808
technique 805–806

pancreatectomy 791, 792
PanNETs see pancreatic neuroendocrine
tumors (PanNET)
papillotomy, endoscopic 1068, 1069–1072,
see also ampulla of Vater
papillectomy 1068, 1069–1072
PD‐1 (programmed death‐1) 858,
PAX4 6

Partington–Rochelle procedure 449, 454,
paraganglioma, duodenal gangliocytic 1053
groove 
para‐aortic lymph node metastases 779, 815
pancreas, interacinar 123
para‐aortic lymph node metastases 779, 815
paralytic ileus, in acute pancreatitis

parasympathetic preganglionic fibers
parasympathetic postganglionic neurons 173, 174
parasympathetic preganglionic fibers
173, 174
parathyroid glands, disorders, hypercalcemia
and acute pancreatitis in 230
parathyroid hormone (PTH), increased, acute
pancreatitis 186, 230
parenchyma, interacinar 123
atrophy, post‐acute pancreatitis 326
destruction, fibrosis in chronic
pancreatitis 337
macrophages in 119
necrosis, in acute pancreatitis 193, 195,
242, 316
see also necrosis, in acute pancreatitis
parenteral nutrition
acute pancreatitis 254–255, 313
chronic pancreatitis 431
pancreatic fistula 319
Partington–Rochelle procedure 449, 454,
459, 491

pasireotide 645, 959, 973
pathogen‐associated molecular patterns
(PAMP) 107
patient education, acute pancreatitis
recurrence risk 324

PAX4 6
PD‐1 (programmed death‐1) 858, 858,
859, 860
antibodies 860, 861
ligands (PD‐L1, PD‐L2) 858, 858, 860, 861
PDX1 gene mutations 24
PDX1 transcription factor 5, 6, 7, 345
Pearson marrow pancreas syndrome 30
pediatric acute pancreatitis 219–229
challenges of 219
diagnosis and criteria for 222, 224
diagnostic difficulties 219
etiology 219–220, 221–222, 223,
224, 336

imaging 224–225
incidence 219, 220
inherited predisposition 221, 222, 224, 227
investigations 220–221
management 225–226
mortality 226, 226
outcomes 226
pathophysiology 220
recurrent 226–227
severity classification 224
pembrolizumab 860
Penrose drains 292, 293
peptide receptor radionuclide therapy (PRRT)
959, 977, 1022
peptide YY (PYY) 89, 126
pancreatic secretion inhibition 89, 126
peripheral neuropathy, pancreatic diabetes 498
perioperative mortality 71, 98
permanent neonatal diabetes mellitus (PNDM) 32
persistent hyperinsulinemic hypoglycemia,
of infancy 31
personalized medicine, pancreatic cancer see uuder pancreatic cancer
PERT see enzyme replacement therapy
pethidine 423
Peutz‐Jeghers syndrome (PJS)
duodenal cancer 1081
IPMN 707
pancreatic cancer 690, 746, 747
pancreatic cystic neoplasms 585
phlebitis, obliterative 516, 517, 525, 527
phosphatidylinositol 3‐kinase (PI3K) 66
phosphatidylinositol 4,5‐bisphosphate (PIP2)
46, 48, 48
phospholipase A2 (PLA‐2) 427
acute lung injury in acute pancreatitis 182
subtypes (I and II) 182
phospholipase C 48
physiology, pancreatic 41–131
see also acinar cell(s); experimental
pancreatitis; pancreatic secretion
(process)
PI3K pathway inhibitors 867
pancreatic cancer therapeutic target 867
regeneration of pancreas 101
PI3K–PKB–mTORC1 pathway
pancreatic growth control 99, 99
translational initiation via 96, 97, 97
PK3CA gene, mutations 583, 585, 938
intraductal tubulopapillary neoplasms 710
pancreatic neuroendocrine tumors 938,
939, 941, 943
PKD1 and PKD2 genes 32
plasma cells
infiltration, tropical chronic
pancreatitis 385
type 1 autoimmune pancreatitis 512–513
Index
sphincter of Oddi (cont’d)
  acute pancreatitis due to 150
  classification 79–80, 80
  diagnostic criteria 79–80, 80
  dyskinetic pattern subtype 80–81
  endoscopic therapy indication 296
  pain, causes 81
  stenotic pattern subtype 80
  ethanol effect 343–344
  functions 76, 77
  innervation 76, 77
  motility 77
  abnormalities 79–81
  animal studies 77
  bioactive agents effect 77
  abnormalities 79–81
  CCK action 78, 78
  humans 78–79
  mucosa 75–76
  phasic contractions 77
  fasting 78–79
  humans 78–79
  inhibition, bile flow 77
  meal ingestion 79
  physiology 75–83, 76
  pressures 78, 78, 79
  spasm 296
  stenosis 80
  tone, regulation 77
  sphincteroplasty 213
  sphincterotomy 80
  acute biliary pancreatitis treatment 152–153, 328
  acute pancreatitis association 150
  ductal stones in chronic pancreatitis 442
  endoscopic see endoscopic sphincterotomy (ES)
  spinal nerve inflammation 175
  spindle cells
  autoimmune pancreatitis type 1 516
  mucinous cystic neoplasm 575, 698, 698
  SPINK1 gene 160, 378
  as disease-modifier gene 161
  mutations 141
  acute pancreatitis and 158, 160, 179
  acute recurrent pancreatitis in children 227
  alcohol-induced pancreatitis 141
  chronic pancreatitis risk 337, 378, 398
  hereditary pancreatitis 35, 377, 378, 398, 746
  loss-of-function 378
  N34S 141, 160, 161, 378
  pancreas divisum, idiopathic pancreatitis 26
  tropical chronic pancreatitis 387
  overexpression, pancreatitis model 179
  pancreatic secretory trypsin inhibitor (PSTI) 160, 178, 398
  SPINK1 protein 160, 178, 398
  autoantibodies against 540, 541
  splanchnic nerves 173, 174
  ablation, pancreatic cancer pain 880–882
  activation, pancreatic secretion and 88
  splanchnic vasoconstruction 167, 167
  splanchnicectomy, thoracoscopic 882
  spleen, preservation, pancreatectomy 644, 650, 791
  splenectomy 469, 644, 650
  splenic artery 252, 644
  splenic vein 13
  occlusion 366
  thrombosis 449, 469
  squamous nests 700, 701
  ST-segment elevation, acute pancreatitis 185
  statins, acute pancreatitis associated 234
  steatohepatia 428
  autoimmune pancreatitis 557
  CFTR-associated pancreatic disease 392
  chronic pancreatitis 361, 384, 399
  exocrine insufficiency 28, 324, 361
  isolated enzyme deficiencies 28
  pancreatic cancer 717
  Shwachman–Diamond syndrome 29
  total pancreatectomy, after 799
  stellate cell system 106
  stellate cells see pancreatic stellate cell (PSC)
  stemness, in cancer cells, PSC role 111
  stenting
  common bile duct 367, 439, 443
  disconnected duct syndrome 319
  endoscopic see endoscopic stenting
  nasopancreatic, preoperative 635
  pancreatic duct see pancreatic duct(s), stenting
  stereotactic body radiotherapy (SBRT) see radiotherapy
  steroids see corticosteroids
  storiform fibrosis, autoimmune pancreatitis 516, 517, 525, 527
  streptozotocin, PanNETs 975, 977, 1006, 1011
  stress response, chronic pancreatitis pathogenesis 334
  stromal cells 3
  reprogramming 868
  targeted therapy, pancreatic cancer 868
  substance P (SP)
  chronic pancreatitis 350, 351–352
  cytokines interacting 352
  functions 351
  receptors 71, 351
  sensory afferents releasing 173
  synthesis, regulation 351
  sulfonylureas 499
  sunitinib 964, 976, 1011
  “super trypsin” 386
  superior mesenteric artery (SMA) 12
  13, 252
  pancreatic cancer involvement 725, 814, 824, 900
  resection 784–785, 816–817, 817
  pancreateoduodenectomy procedure 470, 472
  PanNET invading 996, 997
  resection of nerve plexus around 778, 778, 779
  uncinate process pancreatic cancer 725
  superior mesenteric vein (SMV) 12, 13
  pancreatic cancer invasion 778–779, 814, 824
  resection 784, 815–816
  pancreatic cancer staging 736, 737
  pancreateoduodenectomy 470, 471
  PanNET invading 996, 996, 997, 998
  uncinate process pancreatic cancer 725
  superior mesenteric vein–portal vein (SMV/PV) 649, 651
  invasion, uncinate process cancer 725
  pancreatic cancer 823
  imaging 736, 737
  resectability 814
  staging 773
  robotic pancreateoduodenectomy 806
  surgery see specific procedures, and diseases
  surgical debridement see necrotizing pancreatitis, acute
  susceptibility factors see genetic susceptibility factors
  sweat test, cystic fibrosis 393
  sympathetic nervous system, pancreatic secretion 88
  synthetic lethality 867
  systemic inflammation
  acute pancreatitis 178, 184
  “gut–lymph” hypothesis 166, 167, 167, 170
  systemic inflammatory response syndrome (SIRS)
  acute pancreatitis 181, 182, 183, 184, 258, 261, 268
  fluid resuscitation 254, 258, 313
  necrotizing pancreatitis 271
  pancreatic ischemia and 252
  T
  T cells (T lymphocytes) 856, 857, 857–858
  activation/deactivation 857–858
  autoimmune pancreatitis, type 1 511–512, 512, 513
  B cell interaction 512, 513
  checkpoint inhibitor action 857–858, 858
  in chronic pancreatitis 338
  cytokines 511
  cytotoxic (CD8+) 856, 857, 857
  helper (CD4+) 118, 856, 857
  autoimmune pancreatitis type 1 511, 517
  Th2, autoimmune pancreatitis 511, 517
  response to mesothelin 859
  Treg cells 335, 856, 857
  autoimmune pancreatitis, type 1 511, 512
  T lymphocytes see T cells (T lymphocytes)
  T7-KO gene/mice 67, 68–69, 69
  tail of pancreas
  anatomy 3, 10–11, 790–791
  cancer see under pancreatic cancer.
tumoral intraepithelial neoplasms, ampulla 1047
“two-hit model”, tropical chronic pancreatitis 386
two-pore channel (TPC) 50
tyrosine kinase inhibitor (TKI) 852, 868, 874
ubiquitin protein ligase E3 540
n-recongin 2 (UBR2) 525, 540
UBR1 gene mutations 30
UDP-glucuronyltransferase 1A1 (UGT1A1) 764
culcerative colitis, interleukin-8 (IL-8) 513
ultrasoundraphy
abdominal see abdominal ultrasound
endoluminal, gallstones investigation 151
endoscopic see endoscopic ultrasound (EUS)
intraperitoneal see intraoperative ultrasound (IOS)
peripancreatic tumors 1038–1039
transabdominal see transabdominal ultrasound (TUS)
ultrastructure of pancreas 13–23
diabetes 20–22, 21, 22
exocrine pancreas 13–20, 17, 18, 19, 20
uncinate process 724
pancreatic ductal adenocarcinoma (UPDAC) 724–727, 777
clinical characteristics 725–727, 726
imaging (CT) 737
outcome/prognosis 725, 727, 727
resection 725, 727
PanNET in, surgery 991, 996
PP cells and δ cells 22
uncinectomy 624
undernutrition see malnutrition
unfolded protein response (UPR) 70–71, 336
alcohol effects 138
pancreatic protein synthesis inhibition 98, 98
urine, discoloration 718
v vaccines, therapeutic 858–860, 861
antigen-specific 859–860
neoadjuvant-based 860
whole-cell 858–859, 861
vagal afferent fibers/pathway activation, pancreatic growth and 100
CCK action on pancreatic secretion 86
secretin release and 84–85
serotonin release and 87
vagus nerve 173
efferent fibers 86
pancreatic secretion control 88
parasympathetic preganglionic fibers 173, 174
sensory fibers 173
sphincter of Oddi physiology 77
validation, acute pancreatitis classification 200, 201
valproic acid (VPA) 234, 336
van der Kamer technique 402
vaniloid receptor type 1 (VR1) 352
vascular endothelial growth factor (VEGF) 581, 910
inhibitor (sunitinib) 964, 976, 976, 1011
VEGF-A antibody against (bevacizumab) 976
elevated, serous cystic neoplasm 581
vascular endothelial growth factor receptor (VEGFR) 976
vascular injury, pancreatic parenchymal necrosis 242
vascular invasion, ductal adenocarcinoma 694, 695, 778–779, 814
surgical resection 778–779, 815–817, 823, 824
vascular leak syndrome (VLS) 258, 259
vasoactive intestinal polypeptide (VIP) 100
elevated (serum) 956
see also VIPomavaspessors, acute pancreatitis 261
Vater, ampulla see ampulla of Vater
venusafenil 867
venotomy 845
venous bleeding, post-necrosectomy 286
ventilation, acute pancreatitis 261
ventral pancreas 4, 724
ventral pancreatic bud 4, 5, 24, 724
Verner–Morrison syndrome (WDHA syndrome) 948, 948, 956, 963, 1013, 1032
very low-density lipoproteins (VLDL) 231
VHL gene
function 581, 942
mutations 580–581, 595, 603, 614, 941
germine 581, 585
VHL protein 581
video-assisted retroperitoneal debridement (VARD) 274, 285, 307
laparoscopic, chronic pancreatitis 483–484
video-assisted retroperitoneal debridement, necrosectomy 285, 307
VIPoma 990, 1013
clinical features 719, 719, 948, 948, 1013, 1014
investigations 955, 956
long-term outcome 1032
medical treatment 973, 974, 1016
surgical treatment 963, 990
Virchow, Rudolf 417, 418
Virchow’s node 770
turines, acute pancreatitis and 232, 232
visual defects 429
vitamin A 430
deficiency 429, 430
storage, pancreatic stellate cells 106
vitamin C, supplement, in chronic pancreatitis 436
vitamin D 429–430
deficiency 429, 430, 499
receptor 868
supplementation 430
vitamin E deficiency 429, 430 supplement, in chronic pancreatitis 436, 437 vitamin K deficiency 429, 1042 vitamin supplementation 430, 436, 437 von Hippel–Lindau syndrome (VHL) 33, 569, 942 PanNETs 922, 923, 932, 937, 942, 994 serous cystic neoplasms 573, 574, 580–581, 585, 590, 593, 614, 699 see also VHL gene von Recklinghausen disease see neurofibromatosis type 1

W
X-box binding protein 1 (XBP1) 336 XBP-1 71 Y
Yin Yang 1 (YY1) transcription factor 938, 939 Z
zinc deficiency, tropical chronic pancreatitis 386 Zollinger–Ellison syndrome 948, 961, 963, 965, 1021, 1032 investigations 1009–1010, 1010 medical treatment 974 see also gastrinoma
dzonula occcludens 18 zymogen(s) 178 activation acinar cell protection against 64 acute pancreatitis 65, 66, 178–179 acute pancreatitis models 64–65 biphase pattern 179 cathepsin B role 180–181 colocalization with lysosomes 66, 69 secretion inhibition, pancreatitis models 65, 65–66 see also digestive enzymes; protease(s), pancreatic zymogen granules (ZG) 5 in acinar cells 13, 16, 17, 20, 178 mitochondria location 46–47 Ca2+ release 47, 47–48 enzymes secretion mechanism 43 fragility, alcohol increasing 344 fusion, secretion 16 immature 16 stability decrease by chronic alcohol use 137